

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**Form 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the quarterly period ended September 30, 2022

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

For the transition period from to .  
Commission File No. 001-38403

**CRONOS GROUP INC.**

(Exact name of registrant as specified in its charter)

**British Columbia, Canada**  
(State or other jurisdiction of  
incorporation or organization)

N/A  
(I.R.S. Employer  
Identification No.)

**111 Peter St. Suite 300**  
**Toronto, Ontario**  
(Address of principal executive offices)

**M5V 2H1**  
(Zip Code)

**416-504-0004**

(Registrant's telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

**Securities registered pursuant to Section 12(b) of the Act:**

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, no par value	CRON	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input checked="" type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input type="checkbox"/>	Smaller reporting company	<input type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of November 3, 2022, there were 378,467,867 common shares of the registrant issued and outstanding.

## Table of Contents

### PART I FINANCIAL INFORMATION

Item 1.	<a href="#">Financial Statements.</a>	3
Item 2.	<a href="#">Management’s Discussion and Analysis of Financial Condition and Results of Operations.</a>	30
Item 3.	<a href="#">Quantitative and Qualitative Disclosures About Market Risk.</a>	48
Item 4.	<a href="#">Controls and Procedures.</a>	49

### PART II OTHER INFORMATION

Item 1.	<a href="#">Legal Proceedings.</a>	51
Item 1A.	<a href="#">Risk Factors</a>	51
Item 2.	<a href="#">Unregistered Sales of Equity Securities and Use of Proceeds.</a>	52
Item 3.	<a href="#">Defaults upon Senior Securities.</a>	52
Item 4.	<a href="#">Mine Safety Disclosures.</a>	52
Item 5.	<a href="#">Other Information.</a>	52
Item 6.	<a href="#">Exhibits.</a>	53

Unless otherwise noted or the context indicates otherwise, references in this Quarterly Report on Form 10-Q (this “Quarterly Report”) to the “Company”, “Cronos Group”, “we”, “us” and “our” refer to Cronos Group Inc., its direct and indirect wholly owned subsidiaries and, if applicable, its joint ventures and investments accounted for by the equity method; the term “cannabis” means the plant of any species or subspecies of genus *Cannabis* and any part of that plant, including all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers; the term “U.S. hemp” has the meaning given to term “hemp” in the United States (“U.S.”). Agricultural Improvement Act of 2018 (the “2018 Farm Bill”), including hemp-derived cannabidiol (“CBD”); and the term “U.S. Schedule I cannabis” means cannabis excluding U.S. hemp.

This Quarterly Report contains references to our trademarks and trade names and to trademarks and trade names belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Quarterly Report may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies’ trademarks or trade names to imply a relationship with, or endorsement or sponsorship of us or our business by, any other companies. In addition, this Quarterly Report includes website addresses. These website addresses are intended to provide inactive, textual references only. The information on or referred to on these websites is not part of or incorporated into this Quarterly Report.

All currency amounts in this Quarterly Report are stated in U.S. dollars, which is our reporting currency, unless otherwise noted. All references to “dollars” or “\$” are to U.S. dollars; all references to “C\$” are to Canadian dollars; all references to “A\$” are to Australian dollars; and all references to “ILS” are to New Israeli Shekels.

*(Exchange rates are shown as C\$ per \$)*

	As of		
	September 30, 2022	September 30, 2021	December 31, 2021
Quarter-to-date average rate	1.3053	1.2593	N/A
Spot rate	1.3829	1.2680	1.2746
Year-to-date average rate	1.2829	1.2519	1.2541

All summaries of agreements described herein are qualified by the full text of such agreements (certain of which have been filed as exhibits with the U.S. Securities and Exchange Commission).

**PART I**  
**FINANCIAL INFORMATION**

[Table of Contents](#)

**Item 1. Financial Statements**

**Table of Contents**

<a href="#">Condensed Consolidated Balance Sheets as of September 30, 2022 (Unaudited) and December 31, 2021</a>	4
<a href="#">Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss) for the three and nine months ended September 30, 2022 and 2021 (Unaudited)</a>	5
<a href="#">Condensed Consolidated Statements of Changes in Equity for the three and nine months ended September 30, 2022 and 2021 (Unaudited)</a>	6
<a href="#">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021 (Unaudited)</a>	8
<a href="#">Notes to Condensed Consolidated Financial Statements (Unaudited)</a>	9

	As of September 30, 2022	As of December 31, 2021
	<i>(Unaudited)</i>	<i>(Audited)</i>
<b>Assets</b>		
Current assets		
Cash and cash equivalents	\$ 633,296	\$ 886,973
Short-term investments	255,452	117,684
Accounts receivable, net	19,092	22,067
Other receivables	3,742	5,765
Current portion of loans receivable, net	8,739	5,460
Inventory, net	34,094	32,802
Prepays and other current assets	8,896	8,967
Total current assets	963,311	1,079,718
Equity method investments, net	19,234	16,764
Other investments	94,557	118,392
Non-current portion of loans receivable, net	72,064	80,635
Property, plant and equipment, net	60,582	74,070
Right-of-use assets	5,103	8,882
Goodwill	1,012	1,098
Intangible assets, net	21,428	18,079
Other	168	100
<b>Total assets</b>	<b>\$ 1,237,459</b>	<b>\$ 1,397,738</b>
<b>Liabilities</b>		
Current liabilities		
Accounts payable	\$ 9,989	\$ 11,218
Accrued liabilities	25,629	26,069
Current portion of lease obligation	1,900	2,278
Derivative liabilities	73	14,375
Current portion due to non-controlling interests	379	433
Total current liabilities	37,970	54,373
Non-current portion due to non-controlling interests	1,346	1,913
Non-current portion of lease obligation	4,994	7,095
Deferred income tax liability	1,917	81
<b>Total liabilities</b>	<b>46,227</b>	<b>63,462</b>
<b>Shareholders' equity</b>		
Share capital (authorized for issue as of September 30, 2022 and December 31, 2021: unlimited; shares outstanding as of September 30, 2022 and December 31, 2021: 378,346,260 and 374,952,693, respectively)	605,229	595,497
Additional paid-in capital	38,322	32,465
Retained earnings	569,566	659,416
Accumulated other comprehensive income (loss)	(18,980)	49,865
Total equity attributable to shareholders of Cronos Group	1,194,137	1,337,243
Non-controlling interests	(2,905)	(2,967)
<b>Total shareholders' equity</b>	<b>1,191,232</b>	<b>1,334,276</b>
<b>Total liabilities and shareholders' equity</b>	<b>\$ 1,237,459</b>	<b>\$ 1,397,738</b>

See notes to condensed consolidated interim financial statements.

**Cronos Group Inc.****Condensed Consolidated Statements of Net Income (Loss) and Comprehensive Income (Loss)***(In thousands of U.S dollars, except share and per share amounts, unaudited)*[Table of Contents](#)

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
<b>Net revenue, before excise taxes</b>	\$ 26,584	\$ 24,590	\$ 84,544	\$ 58,092
Excise taxes	(5,661)	(4,183)	(15,527)	(9,452)
<b>Net revenue</b>	20,923	20,407	69,017	48,640
Cost of sales	19,766	21,137	56,814	56,156
Inventory write-down	—	—	—	11,961
<b>Gross profit</b>	1,157	(730)	12,203	(19,477)
<b>Operating expenses</b>				
Sales and marketing	5,923	10,821	16,517	34,284
Research and development	2,569	6,473	10,910	16,774
General and administrative	17,167	32,546	56,540	76,869
Restructuring costs	524	—	4,878	—
Share-based compensation	4,265	2,667	10,567	7,731
Depreciation and amortization	1,713	1,251	4,417	3,029
Impairment loss on goodwill and indefinite-lived intangible assets	—	142	—	235,056
Impairment loss on long-lived assets	—	1,784	3,493	4,739
Total operating expenses	32,161	55,684	107,322	378,482
Operating loss	(31,004)	(56,414)	(95,119)	(397,959)
<b>Other income (expense)</b>				
Interest income, net	7,209	2,064	13,030	6,686
Gain on revaluation of derivative liabilities	375	132,916	14,204	131,290
Share of income (loss) from equity method investments	(1,119)	(1,414)	4,078	(4,172)
Gain on revaluation of financial instruments	17,049	266	19,205	143
Impairment loss on other investments	(28,972)	—	(40,210)	—
Foreign currency transaction gain (loss)	2,387	—	(2,337)	—
Other, net	(693)	7	(556)	1,041
Total other income (expense)	(3,764)	133,839	7,414	134,988
Income (loss) before income taxes	(34,768)	77,425	(87,705)	(262,971)
Income tax expense (benefit)	2,118	(159)	2,172	(159)
Income (loss) from continuing operations	(36,886)	77,584	(89,877)	(262,812)
Income (loss) from discontinued operations	—	82	—	(500)
Net income (loss)	(36,886)	77,666	(89,877)	(263,312)
Net income (loss) attributable to non-controlling interest	105	(250)	(27)	(842)
Net income (loss) attributable to Cronos Group	\$ (36,991)	\$ 77,916	\$ (89,850)	\$ (262,470)
<b>Comprehensive income (loss)</b>				
Net income (loss)	\$ (36,886)	\$ 77,666	\$ (89,877)	\$ (263,312)
Other comprehensive income (loss)				
Foreign exchange gain (loss) on translation	(60,572)	(22,818)	(68,756)	6,936
Comprehensive income (loss)	(97,458)	54,848	(158,633)	(256,376)
Comprehensive income (loss) attributable to non-controlling interests	201	(265)	62	167
<b>Comprehensive income (loss) attributable to Cronos Group</b>	\$ (97,659)	\$ 55,113	\$ (158,695)	\$ (256,543)
<b>Net income (loss) from continuing operations per share</b>				
Basic - continuing operations	\$ (0.10)	\$ 0.21	\$ (0.24)	\$ (0.71)
Diluted - continuing operations	\$ (0.10)	\$ 0.21	\$ (0.24)	\$ (0.71)

See notes to condensed consolidated interim financial statements.

**Cronos Group Inc.****Condensed Consolidated Statements of Changes in Equity****For the three and nine months ended September 30, 2022 and 2021***(In thousands of U.S. dollars, except share amounts, unaudited)*

	Number of shares	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non- controlling interests	Total shareholders' equity
Balance as of January 1, 2022	374,952,693	\$ 595,497	\$ 32,465	\$ 659,416	\$ 49,865	\$ (2,967)	\$ 1,334,276
Activities relating to share-based compensation	347,287	871	2,900	—	—	—	3,771
Net loss	—	—	—	(32,638)	—	(15)	(32,653)
Foreign exchange gain (loss) on translation	—	—	—	—	16,223	(246)	15,977
Balance as of March 31, 2022	375,299,980	\$ 596,368	\$ 35,365	\$ 626,778	\$ 66,088	\$ (3,228)	\$ 1,321,371
Activities relating to share-based compensation	395,156	2,251	(167)	—	—	—	2,084
Share issuance pursuant to research and development milestones	2,201,235	6,007	—	—	—	—	6,007
Net loss	—	—	—	(20,221)	—	(117)	(20,338)
Foreign exchange gain (loss) on translation	—	—	—	—	(24,400)	239	(24,161)
Balance as of June 30, 2022	377,896,371	\$ 604,626	\$ 35,198	\$ 606,557	\$ 41,688	\$ (3,106)	\$ 1,284,963
Activities relating to share-based compensation	449,889	603	3,124	—	—	—	3,727
Net income (loss)	—	—	—	(36,991)	—	105	(36,886)
Foreign exchange gain (loss) on translation	—	—	—	—	(60,668)	96	(60,572)
Balance as of September 30, 2022	378,346,260	\$ 605,229	\$ 38,322	\$ 569,566	\$ (18,980)	\$ (2,905)	\$ 1,191,232

See notes to condensed consolidated interim financial statements.

**Cronos Group Inc.****Condensed Consolidated Statements of Changes in Equity****For the three and nine months ended September 30, 2022 and 2021***(In thousands of U.S. dollars, except share amounts, unaudited)*

	Number of shares	Share capital	Additional paid-in capital	Retained earnings	Accumulated other comprehensive income (loss)	Non- controlling interests	Total shareholders' equity
Balance as of January 1, 2021	360,253,332	\$ 569,260	\$ 34,596	\$ 1,064,509	\$ 42,999	\$ (3,196)	\$ 1,708,168
Activities relating to share-based compensation	11,403,258	15,652	(2,506)	(7,694)	—	—	5,452
Net loss	—	—	—	(161,312)	—	(313)	(161,625)
Foreign exchange gain on translation	—	—	—	—	15,145	1,139	16,284
Balance as of March 31, 2021	<u>371,656,590</u>	<u>\$ 584,912</u>	<u>\$ 32,090</u>	<u>\$ 895,503</u>	<u>\$ 58,144</u>	<u>\$ (2,370)</u>	<u>\$ 1,568,279</u>
Activities relating to share-based compensation	148,957	2,451	278	(63)	—	—	2,666
Top-up rights out-of-period adjustment	—	(14,505)	—	3,227	—	—	(11,278)
Net loss	—	—	—	(179,074)	—	(279)	(179,353)
Foreign exchange gain (loss) on translation	—	—	—	—	13,585	(115)	13,470
Balance as of June 30, 2021	<u>371,805,547</u>	<u>\$ 572,858</u>	<u>\$ 32,368</u>	<u>\$ 719,593</u>	<u>\$ 71,729</u>	<u>\$ (2,764)</u>	<u>\$ 1,393,784</u>
Activities relating to share-based compensation	1,497,314	14,020	(1,995)	(4,232)	—	—	7,793
Net income (loss)	—	—	—	77,916	—	(250)	77,666
Foreign exchange loss on translation	—	—	—	—	(22,803)	(15)	(22,818)
Balance as of September 30, 2021	<u>373,302,861</u>	<u>\$ 586,878</u>	<u>\$ 30,373</u>	<u>\$ 793,277</u>	<u>\$ 48,926</u>	<u>\$ (3,029)</u>	<u>\$ 1,456,425</u>

See notes to condensed consolidated interim financial statements.

	Nine months ended September 30,	
	2022	2021
<b>Operating activities</b>		
Net loss	\$ (89,877)	\$ (263,312)
Adjustments to reconcile net loss to cash used in operating activities:		
Share-based compensation	10,567	7,731
Depreciation and amortization	10,499	8,911
Impairment loss on goodwill and indefinite-lived intangible assets	—	235,056
Impairment loss on long-lived assets	3,493	4,739
Impairment loss on other investments	40,210	—
(Income) loss from investments	(23,283)	4,172
Gain on revaluation of derivative liabilities	(14,204)	(131,290)
Changes in expected credit losses on long-term financial assets	(577)	13,162
Foreign currency transaction loss	2,337	—
Other non-cash operating activities, net	233	(2,831)
Changes in operating assets and liabilities:		
Accounts receivable, net	1,172	(5,747)
Other receivables	1,716	7,431
Prepays and other current assets	(904)	1,054
Inventory	(4,241)	14,335
Accounts payable and accrued liabilities	(1,717)	(11,089)
Cash flows used in operating activities	(64,576)	(117,678)
<b>Investing activities</b>		
Purchase of short-term investments	(275,370)	(119,820)
Proceeds from short-term investments	116,925	135,801
Purchase of other investments	—	(110,392)
(Advances) repayments on loan receivables	2,339	(6,905)
Purchase of property, plant and equipment	(3,087)	(10,651)
Purchase of intangible assets	(1,177)	(1,044)
Other investing activities	70	2,775
Cash flows used in investing activities	(160,300)	(110,236)
<b>Financing activities</b>		
Withholding taxes paid on share-based awards	(2,208)	(13,182)
Other financing activities, net	(69)	18
Cash flows used in financing activities	(2,277)	(13,164)
Effect of foreign currency translation on cash and cash equivalents	(26,524)	5,622
Net change in cash and cash equivalents	(253,677)	(235,456)
Cash and cash equivalents, beginning of period	886,973	1,078,023
Cash and cash equivalents, end of period	\$ 633,296	\$ 842,567
<b>Supplemental cash flow information</b>		
Interest paid	\$ —	\$ —
Interest received	7,734	4,025
Income taxes paid	158	873

See notes to condensed consolidated interim financial statements.

## **1. Background, Basis of Presentation and Accounting Policies**

### **(a) Background**

Cronos Group Inc. (“Cronos Group” or the “Company”) is incorporated in the province of British Columbia and under the *Business Corporations Act* (British Columbia) with principal executive offices at 111 Peter St., Suite 300, Toronto, Ontario, M5V 2H1. The Company’s common shares are currently listed on the Toronto Stock Exchange (“TSX”) and Nasdaq Global Market (“Nasdaq”) under the ticker symbol “CRON.”

Cronos Group is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development and is seeking to build an iconic brand portfolio. Cronos Group’s diverse international brand portfolio includes Spinach<sup>®</sup>, PEACE NATURALS<sup>®</sup>, Lord Jones<sup>®</sup>, Happy Dance<sup>®</sup> and PEACE+<sup>®</sup>.

### **(b) Basis of presentation**

The condensed consolidated interim financial statements of Cronos Group are unaudited. They have been prepared in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”) for interim financial information and with applicable rules and regulations of the U.S. Securities and Exchange Commission relating to interim financial statements. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected for any other reporting period.

These condensed consolidated interim financial statements should be read in conjunction with the Company’s audited consolidated financial statements and related notes included in its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”).

Certain prior year amounts have been reclassified to conform to the current year presentation of our condensed consolidated interim financial statements. These reclassifications had no effect on the reported results of operations and ending shareholders’ equity.

### **(c) Segment information**

Segment reporting is prepared on the same basis that the Company’s chief operating decision maker (the “CODM”) manages the business, makes operating decisions and assesses the Company’s performance. The Company determined that it has the following two reportable segments: U.S. (the “U.S. segment”) and ROW (the “ROW segment”). The U.S. operating segment consists of the manufacture and distribution of U.S. hemp-derived cannabinoid infused products. The ROW operating segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. These two segments represent the geographic regions in which the Company operates and the different product offerings within each geographic region. The results of each segment are regularly reviewed by the CODM to assess the performance of the segment and make decisions regarding the allocation of resources using Adjusted EBITDA (as defined below) as the measure of segment profit or loss. Adjusted EBITDA is defined as earnings before interest, tax, depreciation, non-cash items and items that do not reflect management’s assessment of ongoing business performance.

### **(d) Concentration of risk**

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable and other receivables, and its investing activities, including cash held with banks and financial institutions, short-term investments, loans receivable, and advances to joint ventures. The Company’s maximum exposure to this risk is equal to the carrying amount of these financial assets, which amounted to \$992,385 and \$1,118,684 as of September 30, 2022 and December 31, 2021, respectively.

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan and a failure to make contractual payments for a period of greater than 120 days past due. As of September 30, 2022 and December 31, 2021, the Company had \$2 and \$8, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the ROW segment. As of September 30, 2022 and December 31, 2021, the Company had \$457 and \$104, respectively, in expected credit losses that have been recognized on receivables from contracts with customers in the U.S. segment.

As of September 30, 2022, the Company assessed that there is a concentration of credit risk, as 68% of the Company's accounts receivable were due from three customers with an established credit history with the Company. As of December 31, 2021, 88% of the Company's accounts receivable were due from four customers with an established credit history with the Company.

The Company sells products to a limited number of major customers. Major customers are defined as customers that each individually accounted for greater than 10% of the Company's revenue. During the three months ended September 30, 2022, the Company earned a total net revenue before excise taxes of \$12,094 from three major customers in the ROW segment, together accounting for 56% of the Company's total net revenues before excise taxes. During the three months ended September 30, 2021, the ROW segment earned a total net revenue before excise taxes of \$12,256 from three major customers, together accounting for 60% of the Company's total net revenues before excise taxes. During the nine months ended September 30, 2022, the Company earned a total net revenue before excise taxes of \$36,564 from three major customers in the ROW segment, together accounting for 54% of the Company's total net revenue before excise taxes. During the nine months ended September 30, 2021, the ROW segment earned a total net revenue before excise taxes of \$25,667 from three major customers, together accounting for 53% of the Company's total net revenues before excise taxes. During the three and nine months ended September 30, 2022 and 2021, the U.S. segment had no major customers.

**(e) Adoption of new accounting pronouncements**

On January 1, 2022, the Company adopted ASU No. 2020-06, Debt –Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40) ("ASU No. 2020-06"). ASU No. 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. ASU No. 2020-06 is part of the Financial Accounting Standards Board's ("FASB") simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The adoption of ASU No. 2020-06 did not have an impact on the Company's condensed consolidated interim financial statements.

**(f) New accounting pronouncements not yet adopted**

In March 2022, the FASB issued ASU 2022-02, Financial Instruments – Credit Losses (Topic 326): Troubled Debt Restructurings and Vintage Disclosures ("ASU No. 2022-02"). ASU No. 2022-02 eliminates the existing troubled debt restructuring recognition and measurement guidance, and instead aligns the accounting treatment to that of other loan modifications. The amendments enhance existing disclosure requirements and introduce new requirements related to certain modifications of receivables made to borrowers experiencing financial difficulty. ASU No. 2022-02 also requires that entities disclose current-period gross write-offs by year of origination for financing receivables and net investments in leases. ASU No. 2022-02 is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-02 to have a material impact on its condensed consolidated interim financial statements.

In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions ("ASU No. 2022-03"). ASU No. 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered in measuring fair value. The amendments also require additional disclosures for equity securities subject to contractual sale restrictions. ASU 2022-03 is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years, and is to be adopted prospectively. The Company does not expect the adoption of ASU No. 2022-03 to have a material impact on its condensed consolidated interim financial statements.

**2. Inventory, net**

Inventory, net is comprised of the following items:

	As of September 30, 2022	As of December 31, 2021
Raw materials	\$ 7,863	\$ 9,211
Work-in-progress	11,021	12,405
Finished goods	14,205	10,778
Supplies and consumables	1,005	408
Total	<u>\$ 34,094</u>	<u>\$ 32,802</u>

### 3. Investments

#### (a) Variable interest entities and equity method investments, net

A reconciliation of the carrying amount of the investments in equity method investees, net is as follows:

	Ownership interest	As of September 30, 2022	As of December 31, 2021
Cronos Growing Company Inc. (“Cronos GrowCo”)	50%	\$ 19,234	\$ 16,764
NatuEra S.à.r.l. (“Natuera”)	50%	—	—
		<u>\$ 19,234</u>	<u>\$ 16,764</u>

The following is a summary of the Company’s share of net income (loss) from equity method investments:

	For the three months ended September 30,		For the nine months ended September 30,	
	2022	2021	2022	2021
Cronos GrowCo	\$ (1,119)	\$ (1,214)	\$ 4,078	\$ (1,972)
Natuera	—	(200)	—	(2,200)
	<u>\$ (1,119)</u>	<u>\$ (1,414)</u>	<u>\$ 4,078</u>	<u>\$ (4,172)</u>

#### (b) Other investments

Other investments consist of investments in common shares and options of two companies in the cannabis industry.

##### *PharmaCann, Inc.*

In 2021, the Company purchased an option (the “PharmaCann Option”) to acquire 473,787 shares of Class A Common Stock of PharmaCann Inc. (“PharmaCann”), a vertically integrated cannabis company in the United States, which represented an ownership interest of approximately 10.5% as of December 31, 2021. The PharmaCann Option is classified as an equity security without a readily determinable fair value. The Company has elected to measure the fair value of the PharmaCann Option at cost less impairment, if any, and subsequently adjusted for observable price changes in orderly transactions for the identical or a similar investment of the same issuer. On February 28, 2022, PharmaCann closed the previously announced transaction with LivWell Holdings, Inc. (“LivWell”) pursuant to which PharmaCann acquired LivWell (the “LivWell Transaction”). LivWell is a multi-state cannabis cultivation and retail leader based in Colorado. As a result of the LivWell Transaction, the Company’s ownership percentage in PharmaCann on a fully-diluted basis decreased to approximately 6.4%. As of September 30, 2022, the Company’s ownership percentage in PharmaCann on a fully-diluted basis was approximately 6.3%. The decrease in the Company’s ownership percentage since acquisition does not materially affect the Company’s rights under the PharmaCann Option.

##### *Cronos Australia Limited*

The Company owns approximately 10% of the outstanding common shares of Cronos Australia Limited (“Cronos Australia”). The investment is considered an equity security with a readily determinable fair value. Changes in the fair value of the investment are recorded as gain (loss) on revaluation of financial instruments on the condensed consolidated statements of net income (loss) and comprehensive income (loss). During the three months ended September 30, 2022, Cronos Australia declared a dividend of AUD \$0.01 per ordinary share. Based on the Company’s holding of 55,176,065 ordinary shares in the capital of Cronos Australia, the Company recorded dividend income of \$390 within other, net on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

The following table summarizes the Company's other investments activity:

	As of July 1, 2022	Unrealized gain	Impairment charges	Foreign exchange effect	As of September 30, 2022
PharmaCann	\$ 99,154	\$ —	\$ (28,972)	\$ —	\$ 70,182
Cronos Australia	9,515	17,118	—	(2,258)	24,375
	<u>\$ 108,669</u>	<u>\$ 17,118</u>	<u>\$ (28,972)</u>	<u>\$ (2,258)</u>	<u>\$ 94,557</u>

  

	As of January 1, 2022	Unrealized gain	Impairment charges	Foreign exchange effect	As of September 30, 2022
PharmaCann	\$ 110,392	\$ —	\$ (40,210)	\$ —	\$ 70,182
Cronos Australia	8,000	19,114	—	(2,739)	24,375
	<u>\$ 118,392</u>	<u>\$ 19,114</u>	<u>\$ (40,210)</u>	<u>\$ (2,739)</u>	<u>\$ 94,557</u>

During both the three months ended March 31, 2022 and the three months ended September 30, 2022, the Company identified adverse forecast changes in the financial performance of PharmaCann as indicators of impairment related to the PharmaCann Option and conducted analyses comparing the PharmaCann Option's carrying amount to its estimated fair value. The fair value for the three months ended March 31, 2022 was estimated using a combination of the market and income approaches, and the fair value for the three months ended September 30, 2022 was estimated using the income approach. Under the income approach, significant inputs used in the discounted cash flow method include discount rate, growth rates, and cash flow projections. As a result of these analyses, the Company recorded non-cash impairment charges of \$11,238 and \$28,972 during the three months ended March 31, 2022 and September 30, 2022, respectively, as the difference between the carrying amount of the PharmaCann Option and its estimated fair value in the condensed consolidated statements of net income (loss) and comprehensive income (loss).

During the three and nine months ended September 30, 2021, the Company had no gain or loss on revaluation of other investments. As of September 30, 2022 and December 31, 2021, the Company did not hold any additional other investments.

#### 4. Loans Receivable, net

Loans receivable, net consists of the following:

	As of September 30, 2022	As of December 31, 2021
GrowCo Facility <sup>(i)</sup>	\$ 3,857	\$ 3,138
Add: Current portion of accrued interest	4,882	2,322
Total current portion of loans receivable	<u>8,739</u>	<u>5,460</u>
GrowCo Facility <sup>(i)</sup>	56,740	64,367
Mucci Promissory Note <sup>(ii)</sup>	13,219	14,019
Cannasoul Collaboration Loan <sup>(iii)</sup>	1,955	2,249
Add: Long-term portion of accrued interest	150	—
Total long-term portion of loans receivable	<u>72,064</u>	<u>80,635</u>
Total loans receivable, net	<u>\$ 80,803</u>	<u>\$ 86,095</u>

<sup>(i)</sup> On August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into a senior secured credit agreement for an aggregate principal amount of C\$100,000 (the "GrowCo Facility"). In August 2021, the GrowCo Facility was amended to increase the aggregate principal amount available to C\$105,000. As of September 30, 2022 and December 31, 2021, Cronos GrowCo had outstanding borrowings of C\$101,000 (\$73,035) and C\$104,000 (\$81,598), respectively, from the GrowCo Facility. As of September 30, 2022, Cronos GrowCo had repaid C\$3,000 (\$2,169) under the terms of the GrowCo Facility. The available borrowing capacity under the GrowCo Facility was C\$1,000 (\$723) at both September 30, 2022 and December 31, 2021.

<sup>(ii)</sup> On June 26, 2019, the Company, and the Cronos GrowCo joint venture partner ("Mucci"), entered into a demand promissory note agreement for an aggregate principal amount of C\$16,350 (the "Mucci Promissory Note"). On September 30, 2022, the Mucci Promissory Note was amended and restated to increase the interest rate from 3.95% to the Canadian Prime Rate plus 1.25%, changed the interest payments from quarterly to annual, and deferred Mucci's initial cash interest payment from September 30, 2022 to July 1, 2023. This debt modification resulted in an increase of approximately C\$180 (\$140) in interest income.

<sup>(iii)</sup> As of September 30, 2022 and December 31, 2021, Cannasoul Lab Services Ltd. has received ILS 8,297 (\$2,327) and ILS 8,297 (\$2,664), respectively, from the Cannasoul Collaboration Loan.

Expected credit loss allowances on the Company's long-term financial assets for the three and nine months ended September 30, 2022 and 2021 were comprised of the following items:

	As of July 1, 2022	Increase (decrease) <sup>(i)</sup>	Foreign exchange effect	As of September 30, 2022
GrowCo Facility	\$ 13,293	\$ 74	\$ (929)	\$ 12,438
Mucci Promissory Note	91	1	(6)	86
Cannasoul Collaboration Loan	377	3	(8)	372
	<u>\$ 13,761</u>	<u>\$ 78</u>	<u>\$ (943)</u>	<u>\$ 12,896</u>

	As of July 1, 2021	Increase (decrease)	Foreign exchange effect	As of September 30, 2021
GrowCo Facility	\$ 1,590	\$ 13,074	\$ (202)	\$ 14,462
Mucci Promissory Note	278	(184)	(4)	90
Cannasoul Collaboration Loan	39	272	(9)	302
	<u>\$ 1,907</u>	<u>\$ 13,162</u>	<u>\$ (215)</u>	<u>\$ 14,854</u>

	As of January 1, 2022	Increase (decrease) <sup>(i)</sup>	Foreign exchange effect	As of September 30, 2022
GrowCo Facility	\$ 14,089	\$ (590)	\$ (1,061)	\$ 12,438
Mucci Promissory Note	90	3	(7)	86
Cannasoul Collaboration Loan	415	10	(53)	372
	<u>\$ 14,594</u>	<u>\$ (577)</u>	<u>\$ (1,121)</u>	<u>\$ 12,896</u>

	As of January 1, 2021	Increase (decrease)	Foreign exchange effect	As of September 30, 2021
GrowCo Facility	\$ 1,546	\$ 13,074	\$ (158)	\$ 14,462
Natuera Series A Loan <sup>(ii)</sup>	721	(737)	16	—
Mucci Promissory Note	270	(184)	4	90
Cannasoul Collaboration Loan	26	272	4	302
	<u>\$ 2,563</u>	<u>\$ 12,425</u>	<u>\$ (134)</u>	<u>\$ 14,854</u>

<sup>(i)</sup> During the three months ended September 30, 2022, \$78 was recorded as an increase to general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss) as a result of adjustments to our expected credit losses. During the nine months ended September 30, 2022, \$577 was recorded as a decrease to general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss) as a result of adjustments to our expected credit losses. During the three and nine months ended September 30, 2021, \$13,162 and \$12,425, respectively, were recorded as an increase to general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss) as a result of adjustments to our expected credit losses.

<sup>(ii)</sup> On April 1, 2021, the Company and an affiliate of Agroidea, the other joint venture partner of Natuera, converted all advances made to Natuera under the master loan agreement entered into with Natuera on September 27, 2019, plus accrued interest, into equity of Natuera. As a result, the Company decreased its credit loss allowances by \$737 for the nine months ended September 30, 2021. As of September 30, 2022 and December 31, 2021, loans receivable, net for the Natuera Series A Loan was \$nil.

## 5. Intangible Assets, net

Intangible assets, net are comprised of the following items as of September 30, 2022 and December 31, 2021:

	Useful life (in years)	As of September 30, 2022			Net
		Cost	Accumulated amortization	Accumulated impairment charges	
Software	5	\$ 5,567	\$ (2,120)	\$ (75)	\$ 3,372
Health Canada licenses	17	8,104	(1,736)	(6,368)	—
Ginkgo exclusive licenses <sup>(i)</sup>	10	22,022	(1,362)	(4,347)	16,313
Israeli codes <sup>(ii)</sup>	20	288	(45)	—	243
Total definite-lived intangible assets		<u>35,981</u>	<u>(5,263)</u>	<u>(10,790)</u>	<u>19,928</u>
Lord Jones <sup>®</sup> brand	N/A	1,500	—	—	1,500
Total intangible assets		<u>\$ 37,481</u>	<u>\$ (5,263)</u>	<u>\$ (10,790)</u>	<u>\$ 21,428</u>

	Useful life (in years)	As of December 31, 2021			
		Cost	Accumulated amortization	Accumulated impairment charges	Net
Software	5	\$ 5,644	\$ (1,595)	\$ (4)	\$ 4,045
Health Canada licenses	17	8,793	(1,883)	(6,910)	—
Ginkgo exclusive licenses	10	17,330	(335)	(4,752)	12,243
Israeli codes <sup>(ii)</sup>	20	330	(39)	—	291
<b>Total definite-lived intangible assets</b>		<b>32,097</b>	<b>(3,852)</b>	<b>(11,666)</b>	<b>16,579</b>
Lord Jones <sup>®</sup> brand	N/A	64,000	—	(62,500)	1,500
Trademarks	N/A	142	—	(142)	—
<b>Total intangible assets</b>		<b>\$ 96,239</b>	<b>\$ (3,852)</b>	<b>\$ (74,308)</b>	<b>\$ 18,079</b>

<sup>(i)</sup> In June 2022, the Company announced the achievement of the final productivity target in respect of tetrahydrocannabinavarin (“THCV”) under its collaboration and license agreement (the “Ginkgo Collaboration Agreement”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”). As a result of the achievement of the final productivity target for THCV, the Company issued 2,201,236 common shares at a share price of C\$3.47, and made a cash payment of \$600, for total consideration of C\$8,412 (\$6,522) to Ginkgo through the Ginkgo Collaboration Agreement. The definite-lived intangible asset is being amortized using the straight-line method over its estimated useful life of ten years.

<sup>(ii)</sup> The Israeli codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities.

Amortization expense was \$893 and \$641 for the three months ended September 30, 2022 and 2021, respectively and \$2,014 and \$1,084 for the nine months ended September 30, 2022 and 2021, respectively.

As of September 30, 2022, the estimated future amortization of definite-lived intangible assets is as follows:

	As of September 30, 2022
Remainder of 2022 (3 months)	\$ 751
2023	2,843
2024	2,830
2025	2,545
2026	1,981
2027	1,811
Thereafter	7,167
	<b>\$ 19,928</b>

For the three and nine months ended September 30, 2021, the Company recorded an impairment charge of \$1,784 related to the Ginkgo exclusive licenses intangible assets. Additionally, for the nine months ended September 30, 2021, the Company recorded an impairment charge of \$56,500 on its Lord Jones<sup>®</sup> brand intangible asset. There were no impairment charges on intangible assets for the three and nine months ended September 30, 2022.

## 6. Derivative Liabilities

As of September 30, 2022, Altria Group Inc. (“Altria”) beneficially held 156,573,537 of the Company’s common shares, an approximate 41% ownership interest in the Company (calculated on a non-diluted basis) and one warrant of the Company (the “Altria Warrant”). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would have resulted in Altria holding a total ownership interest in the Company of approximately 52% (calculated on a non-diluted basis). Pursuant to the investor rights agreement between the Company and Altria (the “Investor Rights Agreement”), entered into in connection with the closing of Altria’s investment in the Company (the “Altria Investment”) pursuant to a subscription agreement dated December 7, 2018, the Company granted Altria certain rights, among others, summarized in this note.

The summaries below are qualified entirely by the terms and conditions fully set out in the Investor Rights Agreement and the Altria Warrant, as applicable.

- a. The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to approximately an additional 10% of the common shares of Cronos (84,076,946 common shares as of September 30, 2022) at a per share exercise price of C\$19.00, which expires on March 8, 2023.
- b. The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development (“R&D”) partnership (the “Ginkgo Strategic Partnership”) with Ginkgo), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any issuance of shares by the Company (“Pre-emptive Rights”), at the same price per common share of the Company at which the common shares are sold in the relevant issuance; provided that if the consideration paid in connection with any such issuance is non-cash, the price per common share of the Company that would have been received had such common shares been issued for cash consideration will be determined by an independent committee (acting reasonably and in good faith); provided further that the price per common share of the Company to be paid by Altria pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Strategic Partnership will be C\$16.25 per common share. These rights may not be exercised if Altria’s ownership percentage of the issued and outstanding shares of the Company falls below 20%.
- c. In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter (excluding any convertible securities of the Company owned by Altria or any of its subsidiaries), a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplate an equity component or bona fide acquisitions (including acquisitions of assets or rights under a license or otherwise), mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions (“Top-up Rights”).

Reconciliation of the Company’s derivative liabilities activity are as follows:

	As of July 1, 2022	Revaluation gain	Foreign exchange effect	As of September 30, 2022
(a) Altria Warrant	\$ 491	\$ (336)	\$ (121)	\$ 34
(b) Pre-emptive Rights	16	(18)	2	—
(c) Top-up Rights	67	(21)	(7)	39
	<u>\$ 574</u>	<u>\$ (375)</u>	<u>\$ (126)</u>	<u>\$ 73</u>
	As of July 1, 2021	Revaluation gain	Foreign exchange effect	As of September 30, 2021
(a) Altria Warrant	\$ 150,083	\$ (116,285)	\$ (1,736)	\$ 32,062
(b) Pre-emptive Rights	13,926	(12,430)	(148)	1,348
(c) Top-up Rights	5,554	(4,201)	(235)	1,118
	<u>\$ 169,563</u>	<u>\$ (132,916)</u>	<u>\$ (2,119)</u>	<u>\$ 34,528</u>
	As of January 1, 2022	Revaluation gain	Foreign exchange effect	As of September 30, 2022
(a) Altria Warrant	\$ 13,720	\$ (13,592)	\$ (94)	\$ 34
(b) Pre-emptive Rights	180	(182)	2	—
(c) Top-up Rights	475	(430)	(6)	39
	<u>\$ 14,375</u>	<u>\$ (14,204)</u>	<u>\$ (98)</u>	<u>\$ 73</u>
	As of January 1, 2021	Revaluation gain	Foreign exchange effect	As of September 30, 2021
(a) Altria Warrant	\$ 138,858	\$ (109,099)	\$ 2,303	\$ 32,062
(b) Pre-emptive Rights	12,095	(10,957)	210	1,348
(c) Top-up Rights	12,457	(11,234)	(105)	1,118
	<u>\$ 163,410</u>	<u>\$ (131,290)</u>	<u>\$ 2,408</u>	<u>\$ 34,528</u>

Fluctuations in the expected life of the derivative instruments and the Company's share price are primary drivers for the changes in the derivative valuations during each reporting period. As the expected period of time the derivative liability is expected to be outstanding decreases and the share price decreases, the fair value typically decreases for each related derivative instrument. Weighted-average expected life and share price are two of the significant observable inputs used in the fair value measurement of each of the Company's derivative instruments.

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model using the following inputs:

	As of September 30, 2022		
	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C\$)	\$3.87	\$3.87	\$3.87
Subscription price (per share in C\$)	\$19.00	\$16.25	\$16.25
Weighted-average risk-free interest rate <sup>(i)</sup>	3.67%	3.52%	3.64%
Weighted-average expected life (in years) <sup>(ii)</sup>	0.44	0.25	0.58
Expected annualized volatility <sup>(iii)</sup>	73%	73%	73%
Expected dividend yield	—%	—%	—%

  

	As of December 31, 2021		
	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price at valuation date (per share in C\$)	\$4.98	\$4.98	\$4.98
Subscription price (per share in C\$)	\$19.00	\$16.25	\$16.25
Weighted-average risk-free interest rate <sup>(i)</sup>	0.79%	0.39%	0.50%
Weighted-average expected life (in years) <sup>(ii)</sup>	1.18	0.50	0.80
Expected annualized volatility <sup>(iii)</sup>	80%	80%	80%
Expected dividend yield	—%	—%	—%

<sup>(i)</sup> The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities. As of September 30, 2022 and December 31, 2021, the risk-free interest rate uses a range of approximately 3.52% to 3.80% and 0.16% to 1.10%, respectively, for the Pre-emptive Rights and Top-up Rights.

<sup>(ii)</sup> The expected life represents the period of time, in years, that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked. As of September 30, 2022 and December 31, 2021, the expected life uses a range of approximately 0.25 years to 3.00 years and 0.25 years to 3.75 years, respectively, for the Pre-emptive Rights and Top-up Rights.

<sup>(iii)</sup> Volatility was based on an equally weighted blended historical and implied volatility level of the underlying equity securities of the Company.

The following table quantifies each of the significant inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management's best estimate as of the respective dates. While a decrease in the inputs noted below would cause a decrease in the carrying amount of the derivative liability, there would also be an equal and opposite impact on net income (loss).

	10% decrease as of September 30, 2022		
	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price	\$ 20	\$ —	\$ 12
Weighted-average expected life	18	—	15
Expected annualized volatility	27	—	15

  

	10% decrease as of December 31, 2021		
	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price	\$ 3,970	\$ 80	\$ 123
Weighted-average expected life	2,971	171	133
Expected annualized volatility	5,402	96	155

These inputs are classified as Level 3 on the fair value hierarchy and are subject to volatility and several factors outside the Company's control, which could significantly affect the fair value of these derivative liabilities in future periods.

## 7. Restructuring

In the first quarter of 2022, the Company initiated a strategic plan to realign the business around its brands, centralize functions and evaluate the Company's supply chain (the "Realignment"). As part of the Realignment, on February 28, 2022, the Company's Board of Directors (the "Board") approved plans to leverage the Company's strategic partnerships to improve supply chain efficiencies and reduce manufacturing overhead by exiting its production facility in Stayner, Ontario, Canada (the "Stayner Facility"). The Realignment initiatives being undertaken are intended to position the Company to drive profitable and sustainable growth over time.

The Company expects to incur approximately \$6,100 in connection with the Realignment, including the planned exit of the Stayner Facility, of which \$4,878 has been incurred as of September 30, 2022. Estimated charges related to the exit of the Stayner Facility include employee-related costs such as severance, relocation and other termination benefits, as well as contract termination and other related costs. The Company expects to incur approximately \$1,200 in additional charges related to the Realignment, including the planned exit of the Stayner Facility.

The Company incurred the following restructuring costs by reportable segment:

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
Rest of World	\$ 387	\$ —	\$ 3,396	\$ —
United States	137	—	1,482	—
<b>Total</b>	<b>\$ 524</b>	<b>\$ —</b>	<b>\$ 4,878</b>	<b>\$ —</b>

The following table summarizes the Company's restructuring activity for the three and nine months ended September 30, 2022:

	Accrual as of July 1, 2022	Expenses	Payments/Write-offs	Accrual as of September 30, 2022
Employee termination benefits	\$ 888	\$ 332	\$ (662)	\$ 558
Other restructuring costs	21	192	(192)	21
<b>Total</b>	<b>\$ 909</b>	<b>\$ 524</b>	<b>\$ (854)</b>	<b>\$ 579</b>

	Accrual as of January 1, 2022	Expenses	Payments/Write-offs	Accrual as of September 30, 2022
Employee termination benefits	\$ —	\$ 3,267	\$ (2,709)	\$ 558
Other restructuring costs	—	1,611	(1,590)	21
<b>Total</b>	<b>\$ —</b>	<b>\$ 4,878</b>	<b>\$ (4,299)</b>	<b>\$ 579</b>

## 8. Share-based Compensation

### (a) Share-based award plans

The Company has granted stock options, restricted share units (“RSUs”) and deferred share units (“DSUs”) to employees and non-employee directors under the Stock Option Plan dated May 26, 2015 (the “2015 Stock Option Plan”), the 2018 Stock Option Plan dated June 28, 2018 (the “2018 Stock Option Plan” and, together with the 2015 Stock Option Plan, the “Prior Option Plans”), the Employment Inducement Award Plan #1 (the “Employment Inducement Award Plan”), the 2020 Omnibus Equity Incentive Plan dated March 29, 2020 (the “2020 Omnibus Plan”) and the DSU Plan dated August 10, 2019 (the “DSU Plan”). The Company can no longer make grants under the Prior Option Plans or the Employment Inducement Award Plan.

The following table summarizes the total share-based compensation expense associated with the Company’s stock options, RSUs and liability-classified awards for the three and nine months ended September 30, 2022 and 2021:

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
Stock options	\$ 1,077	\$ 1,886	\$ 3,947	\$ 5,814
RSUs	2,591	781	6,023	1,917
Liability-classified awards <sup>(i)</sup>	597	—	597	—
Total share-based compensation	\$ 4,265	\$ 2,667	\$ 10,567	\$ 7,731

<sup>(i)</sup> Represents share-based payment awards conditionally approved for grant in the three months ended September 30, 2022 to one of the Company’s former executives for a fixed monetary value, but a variable number of shares. These awards are liability-classified until the number of shares is determined.

### (b) Stock options

Vesting conditions for grants of options are determined by the Compensation Committee. The typical vesting for stock option grants made under the 2020 Omnibus Plan is annual vesting over three to five years with a maximum term of ten years. The typical vesting for stock option grants made under the Prior Option Plans is quarterly vesting over three to five years with a maximum term of seven years. The Prior Option Plans did not, and the 2020 Omnibus Plan does not, authorize grants of options with an exercise price below fair market value.

The following is a summary of the changes in stock options for the nine months ended September 30, 2022 and 2021:

	Weighted-average exercise price (C\$) <sup>(i)</sup>	Number of options	Weighted-average remaining contractual term (years)
Balance as of January 1, 2022	\$ 7.75	8,939,330	2.70
Exercise of options	2.81	(2,583,692)	
Cancellation, forfeiture and expiry of options	11.26	(186,992)	
Balance as of September 30, 2022	\$ 9.71	6,168,646	2.97
Exercisable as of September 30, 2022	\$ 9.99	4,037,319	1.99
	Weighted-average exercise price (C\$) <sup>(i)</sup>	Number of options	Weighted-average remaining contractual term (years)
Balance as of January 1, 2021	\$ 5.40	13,755,148	2.30
Issuance of options	9.19	900,000	
Exercise of options	2.14	(5,360,050)	
Cancellation, forfeiture and expiry of options	10.73	(90,274)	
Balance as of September 30, 2021	\$ 7.62	9,204,824	3.15
Exercisable as of September 30, 2021	\$ 6.25	5,844,094	1.46

<sup>(i)</sup> The weighted-average exercise price reflects the conversion of foreign currency-denominated stock options translated into C\$ using the average foreign exchange rate as of the date of issuance.

The following table summarizes stock options outstanding:

	As of September 30, 2022	As of December 31, 2021
2020 Omnibus Plan	2,900,000	2,900,000
2018 Stock Option Plan	1,464,269	1,550,074
2015 Stock Option Plan	1,804,377	4,489,256
Total stock options outstanding	6,168,646	8,939,330

**(c) Restricted share units**

The following is a summary of the changes in RSUs for the nine months ended September 30, 2022 and 2021:

	Weighted-average grant date fair value (C\$) <sup>(iii)</sup>	Number of RSUs
Balance as of January 1, 2022	\$ 9.22	1,225,870
Granted <sup>(i)(ii)</sup>	4.34	5,042,316
Vested and issued	8.56	(771,682)
Cancellation and forfeitures	6.91	(168,610)
Balance as of September 30, 2022	\$ 4.77	5,327,894
	Weighted-average grant date fair value (C\$) <sup>(iii)</sup>	Number of RSUs
Balance as of January 1, 2021	\$ 7.66	948,357
Granted <sup>(i)</sup>	11.06	576,718
Vested and issued	7.11	(115,500)
Cancellation and forfeitures	8.04	(36,971)
Balance as of September 30, 2021	\$ 9.12	1,372,604

<sup>(i)</sup> Except as noted below, RSUs granted in the period vest annually in equal installments over a three-year period from the grant date or vest after a three or five year “cliff-period.” All RSUs are subject to such holder’s continued employment through each vesting date. The vesting of such RSUs is not subject to the achievement of any performance criteria.

<sup>(ii)</sup> Equity grants for 2020, 2021, and 2022 were held back for certain executives of the Company in connection with ongoing investigations by the Securities and Exchange Commission (the “SEC”) and the Ontario Securities Commission (the “OSC”), which were subsequently settled on October 24, 2022. On August 5, 2022, the Compensation Committee approved the release of these held-back equity grants upon the settlement of the SEC and OSC investigations. These RSUs vest in equal installments over a period of three-years from what would have been their original grant dates had the grants not been withheld.

<sup>(iii)</sup> The weighted-average grant date fair value reflects the conversion of foreign currency-denominated RSUs translated into C\$ using the foreign exchange rate as of the date of issuance.

**(d) Deferred share units**

The following is a summary of the changes in DSUs for the nine months ended September 30, 2022 and 2021:

	Financial liability	Number of DSUs
Balance as of January 1, 2022	\$ 408	104,442
Gain on revaluation	(116)	—
Balance as of September 30, 2022	\$ 292	104,442
	Financial liability	Number of DSUs
Balance as of January 1, 2021	\$ 577	83,293
Granting and vesting of DSUs	354	48,913
DSU liabilities settled	(203)	(27,764)
Gain on revaluation	(139)	—
Balance as of September 30, 2021	\$ 589	104,442

**(e) Warrants**

The following is a summary of the changes in warrants for the nine months ended September 30, 2021:

	Weighted-average exercise price (C\$)	Number of warrants
Balance as of January 1, 2021	\$ 0.25	7,987,349
Exercise of warrants	0.25	(7,987,349)
Balance as of September 30, 2021	\$ —	—

As of September 30, 2022, there are no warrants outstanding other than the Altria Warrant. See Note 6 “*Derivative Liabilities*” for further description of the Altria Warrant.

**(f) Liability-classified awards**

During the three months ended September 30, 2022, the Compensation Committee conditionally approved the grant to one of the Company's former executives of share-based compensation awards for a fixed monetary amount, but a variable number of shares. These awards are liability-classified until the number of shares is determined.

	<b>Financial liability</b>
Balance as of January 1, 2022	\$ —
Grants	597
Balance as of September 30, 2022	<u>\$ 597</u>

As of September 30, 2021, there were no liability-classified awards outstanding.

**9. Earnings (Loss) per Share**

Basic and diluted earnings (loss) per share from continuing and discontinued operations are calculated as follows (in thousands, except share and per share amounts):

	<b>Three months ended September 30,</b>		<b>Nine months ended September 30,</b>	
	<b>2022</b>	<b>2021</b>	<b>2022</b>	<b>2021</b>
<b>Basic and diluted earnings (loss) per share computation</b>				
Net income (loss) from continuing operations attributable to the shareholders of Cronos Group	\$ (36,991)	\$ 77,834	\$ (89,850)	\$ (261,970)
Weighted-average number of common shares outstanding for computation for basic earnings per share <sup>(i)</sup>	378,114,160	372,456,354	376,400,902	369,097,920
Basic earnings (loss) from continuing operations per share	<u>\$ (0.10)</u>	<u>\$ 0.21</u>	<u>\$ (0.24)</u>	<u>\$ (0.71)</u>
Loss from discontinued operations attributable to the shareholders of Cronos Group	\$ —	\$ 82	\$ —	\$ (500)
Weighted-average number of common shares outstanding from computation for basic earnings per share	378,114,160	372,456,354	376,400,902	369,097,920
Basic earnings (loss) from discontinued operations per share	<u>\$ 0.00</u>	<u>\$ 0.00</u>	<u>\$ 0.00</u>	<u>\$ 0.00</u>
<b>Diluted earnings (loss) per share computation</b>				
Net income (loss) used in the computation of basic earnings (loss) from continuing operations per share	\$ (36,991)	\$ 77,834	\$ (89,850)	\$ (261,970)
Adjustment for exercise of rights on derivative liabilities	—	—	—	—
Net income (loss) used in the computation of diluted earnings (loss) from continuing operations per share	<u>\$ (36,991)</u>	<u>\$ 77,834</u>	<u>\$ (89,850)</u>	<u>\$ (261,970)</u>
Weighted-average number of common shares outstanding used in the computation of basic earnings (loss) per share	378,114,160	372,456,354	376,400,902	369,097,920
Dilutive effect of stock options	—	2,507,471	—	—
Dilutive effect of RSUs	—	581,481	—	—
Dilutive effect of Top-up Rights – market price	—	107,942	—	—
Weighted-average number of common shares for computation of diluted earnings (loss) from continuing operations per share <sup>(i)</sup>	378,114,160	375,653,248	376,400,902	369,097,920
Diluted earnings (loss) per share from continuing operations	<u>\$ (0.10)</u>	<u>\$ 0.21</u>	<u>\$ (0.24)</u>	<u>\$ (0.71)</u>
Income (loss) from discontinued operations attributable to the shareholders of Cronos Group	\$ —	\$ 82	\$ —	\$ (500)
Weighted-average number of common shares for computation of diluted earnings (loss) from discontinued operations per share	378,114,160	375,653,248	376,400,902	369,097,920
Diluted loss from discontinued operations per share	<u>\$ 0.00</u>	<u>\$ 0.00</u>	<u>\$ 0.00</u>	<u>\$ 0.00</u>

<sup>(i)</sup> In computing diluted earnings per share, incremental common shares are not considered in periods in which a net loss is reported as the inclusion of the common share equivalents would be anti-dilutive.

For the three months ended September 30, 2022 and 2021, total securities of 117,100,621 and 118,255,677, respectively, and for the nine months ended September 30, 2022 and 2021, total securities of 118,304,608 and 127,137,014, respectively, were not included in the computation of diluted shares outstanding, because the effect would be anti-dilutive.

## 10. Segment Information

The tables below set forth our condensed consolidated results of operations by segment. The Company's condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that the Company will achieve in future periods. Segment data was as follows for the three and nine months ended September 30, 2022 and 2021:

	Three months ended September 30, 2022			
	United States	Rest of World	Corporate	Total
Cannabis flower	\$ —	\$ 13,674	\$ —	\$ 13,674
Cannabis extracts	514	6,627	—	7,141
Other	—	108	—	108
Net revenue	<u>\$ 514</u>	<u>\$ 20,409</u>	<u>\$ —</u>	<u>\$ 20,923</u>
Share of loss from equity method investments	\$ —	\$ (1,119)	\$ —	\$ (1,119)
Total assets	\$ 395,732	\$ 277,165	\$ 564,562	\$ 1,237,459
Depreciation and amortization	84	1,629	—	1,713
Adjusted EBITDA	(4,864)	(11,423)	(5,410)	(21,697)
	Three months ended September 30, 2021			
	United States	Rest of World	Corporate	Total
Cannabis flower	\$ —	\$ 15,306	\$ —	\$ 15,306
Cannabis extracts	2,100	2,786	—	4,886
Other	—	215	—	215
Net revenue	<u>\$ 2,100</u>	<u>\$ 18,307</u>	<u>\$ —</u>	<u>\$ 20,407</u>
Share of loss from equity method investments	\$ —	\$ (1,414)	\$ —	\$ (1,414)
Total assets	\$ 474,915	\$ 376,569	\$ 683,715	\$ 1,535,199
Depreciation and amortization	70	1,181	—	1,251
Adjusted EBITDA	(12,200)	(29,760)	(4,813)	(46,773)
	Nine months ended September 30, 2022			
	United States	Rest of World	Corporate	Total
Cannabis flower	\$ —	\$ 48,038	\$ —	\$ 48,038
Cannabis extracts	4,301	16,197	—	20,498
Other	—	481	—	481
Net revenue	<u>\$ 4,301</u>	<u>\$ 64,716</u>	<u>\$ —</u>	<u>\$ 69,017</u>
Share of income from equity method investments	\$ —	\$ 4,078	\$ —	\$ 4,078
Total assets	\$ 395,732	\$ 277,165	\$ 564,562	\$ 1,237,459
Depreciation and amortization	267	4,150	—	4,417
Adjusted EBITDA	(15,827)	(23,843)	(19,726)	(59,396)

	Nine months ended September 30, 2021			
	United States	Rest of World	Corporate	Total
Cannabis flower	\$ —	\$ 36,337	\$ —	\$ 36,337
Cannabis extracts	6,768	5,020	—	11,788
Other	—	515	—	515
Net revenue	<u>\$ 6,768</u>	<u>\$ 41,872</u>	<u>\$ —</u>	<u>\$ 48,640</u>
Share of loss from equity method investments	\$ —	\$ (4,172)	\$ —	\$ (4,172)
Total assets	\$ 474,915	\$ 376,569	\$ 683,715	\$ 1,535,199
Depreciation and amortization	209	2,820	—	3,029
Adjusted EBITDA	(32,421)	(84,549)	(16,136)	(133,106)

The following tables set forth a reconciliation of net income (loss) as determined in accordance with U.S. GAAP to Adjusted EBITDA for the periods indicated:

	Three months ended September 30, 2022			
	United States	Rest of World	Corporate	Total
Net income (loss)	\$ (33,223)	\$ 2,817	\$ (6,480)	\$ (36,886)
Interest income, net	(1,418)	(5,791)	—	(7,209)
Income tax expense	—	2,118	—	2,118
Share of loss from equity method investments	—	1,119	—	1,119
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(375)	—	(375)
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(17,049)	—	(17,049)
Impairment loss on other investment <sup>(vi)</sup>	28,972	—	—	28,972
Foreign currency transaction gain	—	(2,387)	—	(2,387)
Other, net <sup>(vii)</sup>	159	534	—	693
Restructuring costs <sup>(ix)</sup>	137	387	—	524
Share-based compensation <sup>(x)</sup>	8	4,257	—	4,265
Financial statement review costs <sup>(xi)</sup>	—	—	1,070	1,070
Depreciation and amortization	501	2,947	—	3,448
Adjusted EBITDA	<u>\$ (4,864)</u>	<u>\$ (11,423)</u>	<u>\$ (5,410)</u>	<u>\$ (21,697)</u>

	<b>Three months ended September 30, 2021</b>			
	<b>United States</b>	<b>Rest of World</b>	<b>Corporate</b>	<b>Total</b>
Net income (loss)	\$ (13,499)	\$ 97,198	\$ (6,033)	\$ 77,666
Interest income, net	(4)	(2,060)	—	(2,064)
Income tax benefit	—	(159)	—	(159)
Share of loss from equity method investments	—	1,414	—	1,414
Impairment loss on goodwill and indefinite-lived intangible assets <sup>(i)</sup>	105	37	—	142
Impairment loss on long-lived assets <sup>(ii)</sup>	—	1,784	—	1,784
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(132,916)	—	(132,916)
Transaction costs <sup>(iv)</sup>	—	—	542	542
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(266)	—	(266)
Other, net <sup>(vii)</sup>	—	(7)	—	(7)
Income from discontinued operations <sup>(viii)</sup>	—	(82)	—	(82)
Share-based compensation <sup>(x)</sup>	967	1,700	—	2,667
Financial statement review costs <sup>(xi)</sup>	—	—	678	678
Depreciation and amortization	231	3,597	—	3,828
Adjusted EBITDA	<u>\$ (12,200)</u>	<u>\$ (29,760)</u>	<u>\$ (4,813)</u>	<u>\$ (46,773)</u>

	<b>Nine months ended September 30, 2022</b>			
	<b>United States</b>	<b>Rest of World</b>	<b>Corporate</b>	<b>Total</b>
Net loss	\$ (59,937)	\$ (3,928)	\$ (26,012)	\$ (89,877)
Interest income, net	(1,873)	(11,157)	—	(13,030)
Income tax expense	—	2,172	—	2,172
Share of income from equity method investments	—	(4,078)	—	(4,078)
Impairment loss on long-lived assets <sup>(ii)</sup>	—	3,493	—	3,493
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(14,204)	—	(14,204)
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(19,205)	—	(19,205)
Impairment loss on other investment <sup>(vi)</sup>	40,210	—	—	40,210
Foreign currency transaction loss	—	2,337	—	2,337
Other, net <sup>(vii)</sup>	159	397	—	556
Restructuring costs <sup>(ix)</sup>	1,482	3,396	—	4,878
Share-based compensation <sup>(x)</sup>	2,917	7,650	—	10,567
Financial statement review costs <sup>(xi)</sup>	—	—	6,286	6,286
Depreciation and amortization	1,215	9,284	—	10,499
Adjusted EBITDA	<u>\$ (15,827)</u>	<u>\$ (23,843)</u>	<u>\$ (19,726)</u>	<u>\$ (59,396)</u>

	Nine months ended September 30, 2021			
	United States	Rest of World	Corporate	Total
Net income (loss)	\$ (273,438)	\$ 34,678	\$ (24,552)	\$ (263,312)
Interest income, net	(27)	(6,659)	—	(6,686)
Income tax benefit	—	(159)	—	(159)
Share of loss from equity method investments	—	4,172	—	4,172
Impairment loss on goodwill and indefinite-lived intangible assets <sup>(i)</sup>	235,019	37	—	235,056
Impairment loss on long-lived assets <sup>(ii)</sup>	2,955	1,784	—	4,739
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(131,290)	—	(131,290)
Transaction costs <sup>(iv)</sup>	—	—	3,801	3,801
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(143)	—	(143)
Other, net <sup>(vii)</sup>	—	(1,041)	—	(1,041)
Loss from discontinued operations <sup>(viii)</sup>	—	500	—	500
Share-based compensation <sup>(x)</sup>	2,534	5,197	—	7,731
Financial statement review costs <sup>(xi)</sup>	—	—	4,615	4,615
Depreciation and amortization	536	8,375	—	8,911
Adjusted EBITDA	<u>\$ (32,421)</u>	<u>\$ (84,549)</u>	<u>\$ (16,136)</u>	<u>\$ (133,106)</u>

- <sup>(i)</sup> For the three and nine months ended September 30, 2021, impairment on goodwill and indefinite-lived intangible assets relates to impairment on goodwill and indefinite-lived intangible assets related to the Company's U.S. segment.
- <sup>(ii)</sup> For the nine months ended September 30, 2022, impairment loss on long-lived assets related to the Company's decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter of 2022. For the three months ended September 30, 2021, impairment loss on long-lived assets relates to an impairment on property, plant and equipment in the U.S. segment. For the nine months ended September 30, 2021, impairment loss on long-lived assets relates to the aforementioned impairment loss on property, plant and equipment as well as an impairment loss on leased premises in the U.S. segment from the first quarter of 2021. See Note 13 "Impairment Loss on Long-lived Assets."
- <sup>(iii)</sup> For the three and nine months ended September 30, 2022 and 2021, gain on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 6 "Derivative Liabilities."
- <sup>(iv)</sup> For the three and nine months ended September 30, 2021, transaction costs represent legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss).
- <sup>(v)</sup> For the three and nine months ended September 30, 2022, gain on revaluation of financial instruments related primarily to the Company's equity securities in Cronos Australia. For three and nine months ended September 30, 2021, gain on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs.
- <sup>(vi)</sup> For the three and nine months ended September 30, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 3 "Investments."
- <sup>(vii)</sup> For the three months ended September 30, 2022, other, net related to \$1,083 loss on disposal of assets and \$390 of dividends declared by Cronos Australia on the Company's 55,176,065 ordinary shares in the capital of Cronos Australia. For the nine months ended September 30, 2022, other, net related to \$946 loss on disposal of assets and \$390 of dividends declared by Cronos Australia on the Company's 55,176,065 ordinary shares in the capital of Cronos Australia. For the three and nine months ended September 30, 2021, other, net primarily related to gain recorded on sale of an asset previously designated as held-for-sale in the first quarter of 2021.
- <sup>(viii)</sup> For the three and nine months ended September 30, 2021, loss (income) from discontinued operations related to the discontinuance of Original B.C. Ltd. ("OGBC").
- <sup>(ix)</sup> For the three and nine months ended September 30, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment, including the planned exit of the Stayner Facility. See Note 7 "Restructuring."
- <sup>(x)</sup> For the three and nine months ended September 30, 2022 and 2021, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under the Company's share-based award plans as described in Note 8 "Share-based Compensation."
- <sup>(xi)</sup> For the three and nine months ended September 30, 2022 and 2021, financial statement review costs include costs and reserves taken related to the restatements of the Company's 2019 and second quarter 2021 interim financial statements, costs related to the Company's responses to requests for information from various regulatory authorities relating to such restatements and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement.

Net revenue attributed to a geographic region based on the location of the customer were as follows:

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
Canada	\$ 13,370	\$ 14,186	\$ 41,335	\$ 32,432
Israel	7,039	3,752	23,381	8,580
United States	514	2,100	4,301	6,768
Other countries	—	369	—	860
Net revenue	\$ 20,923	\$ 20,407	\$ 69,017	\$ 48,640

## 11. Commitments and Contingencies

### (a) Commitments

There have been no material changes in the information regarding commitments as disclosed in the Company's Annual Report.

### (b) Contingencies

The Company is subject to various legal proceedings in the ordinary course of its business and in connection with its marketing, distribution and sale of its products. Many of these legal proceedings are in the early stages of litigation and seek damages that are unspecified or not quantified. Although the outcome of these matters cannot be predicted with certainty, the Company does not believe these legal proceedings, individually or in the aggregate, will have a material adverse effect on its financial condition but could be material to its results of operations for a quarterly period depending, in part, on its results for that quarter.

#### (i) Class action complaints relating to restatement of 2019 interim financial statements

On March 11 and 12, 2020, two alleged shareholders of the Company separately filed two putative class action complaints in the U.S. District Court for the Eastern District of New York against the Company and its Chief Executive Officer and now former Chief Financial Officer. The court has consolidated the cases, and the consolidated amended complaint alleges violations of Section 10(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder against all defendants, and Section 20(a) of the Exchange Act against the individual defendants. The consolidated amended complaint generally alleges that certain of the Company's prior public statements about revenues and internal control were incorrect based on the Company's disclosures relating to the Audit Committee of the Board's review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel. The consolidated amended complaint does not quantify a damage request. Defendants moved to dismiss on February 8, 2021.

On June 3, 2020, an alleged shareholder filed a Statement of Claim, as amended on August 12, 2020, in the Ontario Superior Court of Justice in Toronto, Ontario, Canada, seeking, among other things, an order certifying the action as a class action on behalf of a putative class of shareholders and damages of an unspecified amount. The Amended Statement of Claim names (i) the Company, (ii) its Chief Executive Officer, (iii) now former Chief Financial Officer, (iv) former Chief Financial Officer and Chief Commercial Officer, and (v) current and former members of the Board as defendants and alleges breaches of the Ontario Securities Act, oppression under the Ontario Business Corporations Act and common law misrepresentation. The Amended Statement of Claim generally alleges that certain of the Company's prior public statements about revenues and internal control were misrepresentations based on the Company's March 2, 2020 disclosure that the Audit Committee of the Board was conducting a review of the appropriateness of revenue recognized in connection with certain bulk resin purchases and sales of products through the wholesale channel, and the Company's subsequent restatement. The Amended Statement of Claim does not quantify a damage request. On June 28, 2021, the Court dismissed motions brought by the plaintiff for leave to commence a claim for misrepresentation under the Ontario Securities Act and for certification of the action as a class action. The plaintiff appealed the Court's dismissal of the motions only with respect to the Company, the Chief Executive Officer, and the now former Chief Financial Officer; the remaining defendants were dismissed from the matter with prejudice, and the Company and all individual defendants agreed not to seek costs from plaintiff in connection with the dismissal of the motions. On September 26, 2022, the Court of Appeal for Ontario reversed the Superior Court's dismissal of the leave and certification motions, granted the plaintiff leave to proceed to bring a claim for misrepresentation under the Ontario Securities Act, and remitted the certification motion back to the Superior Court.

#### (ii) Regulatory reviews relating to restatements

The Company has been responding to requests for information from various regulatory authorities relating to its previously disclosed restatement of its financial statements for the first three quarters of 2019 as well as the previously disclosed restatement of the second quarter of 2021 interim financial statements (collectively, the "Restatements"). The Company has been responding to all such requests for information and cooperating with all regulatory authorities.

### ***SEC Settlement***

On October 24, 2022, the SEC issued an Order Instituting Cease-and-Desist Proceedings Pursuant to Section 8(a) of the Securities Act of 1933 (the “Securities Act”) and Section 21(c) of the Exchange Act, Making Findings, and Imposing a Cease-and-Desist Order (the “Settlement Order”) resolving the Restatements.

The Company has agreed to settle with the SEC, without admitting or denying the allegations described in the Settlement Order. The Settlement Order fully and finally disposes of the investigation of the Company by the SEC into the Restatements without the payment of any civil penalty or other amount.

The Settlement Order required the Company to cease and desist from committing or causing any violations and any future violations of Section 17(a) of the Securities Act, Sections 10(b), 13(a), 13(b)(2)(B) of the Exchange Act and Rules 10b-5, 13a-13, 13a-15(a), 13a-16 and 12b-20 thereunder. Additionally, the Company agreed to certain undertakings, which include, among other things, retaining a qualified independent consultant (the “Consultant”) to engage in a review of, and make recommendations with respect to, certain of the Company’s internal accounting controls and internal control over financing reporting.

As a result of the Settlement Order, the Company will (i) lose its status as a well-known seasoned issuer for a period of three years, (ii) be unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years and (iii) be unable to rely on the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995 for a period of three years.

### ***OSC Settlement***

On October 24, 2022, the Ontario Capital Markets Tribunal approved a settlement agreement (the “Settlement Agreement”) between the Company and the staff of the OSC, resolving the Restatements.

Pursuant to the terms of the Settlement Agreement, which fully and finally disposes the investigation of the Company by the OSC, Cronos agreed to pay a total of C\$1.34 million to fully settle the matter, and acknowledged that it had failed to comply with the requirement under Section 77 of the Securities Act (Ontario) to file interim financial reports in the manner set out therein and had acted in a manner contrary to the public interest. Additionally, the Company agreed to retain the Consultant to engage in a review of, and make recommendations with respect to, certain of the Company’s internal accounting controls and internal control over financing reporting, on substantially the same terms as were required by the SEC pursuant the Settlement Order.

### ***(iii) Litigation relating to marketing, distribution and sale of products***

On June 16, 2020, an alleged consumer filed a Statement of Claim on behalf of a class in the Court of Queen’s Bench of Alberta in Alberta, Canada, against the Company and other Canadian cannabis manufacturers and/or distributors. On December 4, 2020, a Third Amended Statement of Claim was filed, which added a second alleged consumer. The Third Amended Statement of Claim alleges claims related to the defendants’ advertised content of cannabinoids in cannabis products for medicinal use on or after June 16, 2010 and cannabis products for adult use on or after October 17, 2018. The Third Amended Statement of Claim seeks a total of C\$500 million for breach of contract, compensatory damages, and unjust enrichment or such other amount as may be proven in trial and C\$5 million in punitive damages against each defendant, including the Company. The Third Amended Statement of Claim also seeks interest and costs associated with the action. The Company has not responded to the Third Amended Statement of Claim. On January 31, 2022, upon consent of the Company and the plaintiffs, the court dismissed the case in its entirety as to the Company.

A number of claims, including purported class actions, have been brought in the U.S. against companies engaged in the U.S. hemp business alleging, among other things, violations of state consumer protection, health and advertising laws. On April 8, 2020, a putative class action complaint was filed in the U.S. District Court for the Central District of California against Redwood Holding Group, LLC (“Redwood”), alleging violations of California’s Unfair Competition Law, False Advertising Law, Consumers Legal Remedies Act, and breaches of the California Commercial Code for breach of express warranties and implied warranty of merchantability with respect to Redwood’s marketing and sale of U.S. hemp products. The complaint did not quantify a damage request. On April 10, 2020, the class action complaint was dismissed for certain pleading deficiencies and the plaintiff was granted leave until April 24, 2020 to amend the complaint to establish federal subject matter jurisdiction. On April 28, 2020, the action was dismissed without prejudice for failure to prosecute and for failure to comply with a court order. As of the date of this Quarterly Report, the plaintiff has not refiled the complaint.

The Company expects litigation and regulatory proceedings relating to the marketing, distribution and sale of its products to increase.

## 12. Fair Value Measurements

The Company complies with ASC 820 *Fair Value Measurements* for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values are determined by:

- Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves.
- Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.

The following tables present information about the Company's assets and liabilities that are measured at fair value on a recurring basis:

	September 30, 2022			
	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 633,296	\$ —	\$ —	\$ 633,296
Short-term investments	255,452	—	—	255,452
Other investments <sup>(i)</sup>	24,375	—	—	24,375
Derivative liabilities	—	—	73	73

  

	December 31, 2021			
	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$ 886,973	\$ —	\$ —	\$ 886,973
Short-term investments	117,684	—	—	117,684
Other investments <sup>(i)</sup>	8,000	—	—	8,000
Derivative liabilities	—	—	14,375	14,375

<sup>(i)</sup> As of September 30, 2022 and December 31, 2021, the Company's influence on Cronos Australia is deemed non-significant and the investment is considered an equity security with a readily determinable fair value. See Note 3 "Investments" for additional information.

There were no transfers between fair value categories during the periods presented.

## 13. Impairment Loss on Long-lived Assets

### (a) Right-of-use assets and property, plant, and equipment, net

During the nine months ended September 30, 2022, the Company recognized an impairment charge of \$1,986 related to the right-of-use lease asset associated with the Company's corporate headquarters, encompassing approximately 29,000 square feet, in Toronto, Ontario, Canada, for which the Company determined it would seek a sublease. In addition, the Company recognized an impairment charge of \$1,507 during the nine months ended September 30, 2022 related to leasehold improvements and other office equipment that it plans to include in any potential sublease agreement. The determination to seek a sublease of the property and include leasehold improvements and other office equipment in any potential sublease agreement triggered the impairment charges. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

During the nine months ended September 30, 2021, the Company recognized an impairment charge of \$1,039 related to leasehold improvements located within leased premises, encompassing approximately 6,000 square feet, in Los Angeles, California, which the Company determined it no longer had plans to use. The significant change in the extent and manner in which the leasehold improvements are being used and the expectation that, more likely than not, the leasehold improvements will be disposed of before the end of their useful life triggered an impairment. The right-of-use lease asset associated with the leasehold improvements was also written down as a result of the Company's decision to no longer use the leased premises. The Company recognized an impairment charge on the de-recognition of the right-of-use asset of \$702 during the nine months ended September 30, 2021. Both of the impairment charges are recognized as impairment loss on long-lived assets on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

Additionally, during the nine months ended September 30, 2021, the Company reassessed the existence of impairment indicators on property, plant and equipment associated with sales channels in the U.S. segment. The Company determined that slower actual revenue growth as compared to previous growth forecasts and significant pricing pressures brought about by increased competition and aggressive discounting in sales channels in the U.S. segment represented indicators of impairment. As a result, a quantitative impairment analysis was required as of June 30, 2021. As such, the Company reassessed its estimates and forecasts as of June 30, 2021, to determine the fair values of the property, plant and equipment using an undiscounted cash flow methodology. Significant inputs include growth rates and cash flow projections. As a result of the analysis as of June 30, 2021, the Company concluded the carrying amount of the property, plant and equipment associated with sales channels in the U.S. segment exceeded its fair value, which resulted in impairment charges of \$1,214 on the condensed consolidated statements of net income (loss) and comprehensive income (loss) for the nine months ended September 30, 2021.

No impairment charges were recorded during the three months ended September 30, 2022 and 2021 on property, plant and equipment and right-of-use assets.

**(b) Intangible assets, net**

During the three and nine months ended September 30, 2021, the Company recognized an impairment charge of \$1,784 on definite-lived intangible assets for the difference between the consideration paid to Ginkgo for the achievement of certain milestones in connection with the Ginkgo Collaboration Agreement and the fair value of the Ginkgo exclusive license intellectual property. See Note 5 “*Intangible Assets, net*” for additional information. The impairment charge is recognized as impairment loss on long-lived assets on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

No impairment charges were recorded during the three and nine months ended September 30, 2022 on definite-lived intangible assets.

**14. Related Party Transactions**

**(a) Altria**

On March 8, 2019, in connection with the Altria Investment, Altria, through certain of its wholly owned subsidiaries, purchased a 45% equity interest in the Company. As of September 30, 2022, Altria beneficially held an approximately 41% ownership interest in the Company (calculated on a non-diluted basis).

The Company incurred the following expenses for consulting services from Altria Pinnacle LLC, a subsidiary of Altria (“Altria Pinnacle”):

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
Altria Pinnacle - expense	\$ —	\$ 424	\$ 28	\$ 436

As of both September 30, 2022 and December 31, 2021, the Company had no payables outstanding to Altria Pinnacle.

**(b) Cronos GrowCo**

The Company holds a variable interest in Cronos GrowCo through its ownership of 50% of Cronos GrowCo’s common shares and senior secured debt in Cronos GrowCo. See Note 3 “*Investments*” for additional information.

The Company made the following purchases of cannabis products from Cronos GrowCo:

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
Cronos GrowCo - purchases	\$ 2,158	\$ 278	\$ 10,973	\$ 812

As of September 30, 2022 and December 31, 2021, the Company had payables outstanding to Cronos GrowCo of \$972 and \$82, respectively.

Additionally, on August 23, 2019, the Company, as lender, and Cronos GrowCo, as borrower, entered into the GrowCo Facility. See Note 4 “*Loans Receivable, net*” for additional information.

## Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read together with other information, including Cronos Group's condensed consolidated interim financial statements and the related notes to those statements, included in Part I, Item 1 of this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022 (this "Quarterly Report"), consolidated financial statements appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the "Annual Report"), Part I, Item 1A, Risk Factors, of the Annual Report and Part II, Item 1A, Risk Factors, of this Quarterly Report.

### Forward-Looking Statements

This Quarterly Report, the documents incorporated into this Quarterly Report by reference, other reports we file with, or furnish to, the U.S. Securities and Exchange Commission ("SEC") and other regulatory agencies, and statements by our directors, officers, other employees and other persons authorized to speak on our behalf contain information that may constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws and court decisions (collectively, "Forward-Looking Statements"), which are based upon our current internal expectations, estimates, projections, assumptions and beliefs. All information that is not clearly historical in nature may constitute Forward-Looking Statements. In some cases, Forward-Looking Statements can be identified by the use of forward-looking terminology, such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, expressions and phrases, including negative and grammatical variations thereof, or statements that certain events or conditions "may" or "will" happen, or by discussion of strategy. Forward-Looking Statements include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of historical fact.

Forward-Looking Statements include, but are not limited to, statements with respect to:

- the impact of the ongoing military conflict between Russia and Ukraine (and resulting sanctions) on our business, financial condition and results of operations or cash flows;
- the uncertainties associated with the COVID-19 pandemic, including our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic, the ability to continue our production, distribution and sale of our products, and demand for and the use of our products by consumers;
- laws and regulations and any amendments thereto applicable to our business and the impact thereof, including uncertainty regarding the application of United States ("U.S.") state and federal law to U.S. hemp (including CBD and other U.S. hemp-derived cannabinoids) products and the scope of any regulations by the U.S. Food and Drug Administration (the "FDA"), the U.S. Drug Enforcement Administration (the "DEA"), the U.S. Federal Trade Commission (the "FTC"), the U.S. Patent and Trademark Office (the "PTO") and any state equivalent regulatory agencies over U.S. hemp (including CBD and other U.S. hemp-derived cannabinoids) products;
- the laws and regulations and any amendments thereto relating to the U.S. hemp industry in the U.S., including the promulgation of regulations for the U.S. hemp industry by the U.S. Department of Agriculture (the "USDA") and relevant state regulatory authorities;
- expectations related to our announced realignment (the "Realignment") and any progress, challenges and effects related thereto as well as changes in strategy, metrics, investments, reporting structure, costs, operating expenses, employee turnover and other changes with respect thereto;
- the timing of our planned exit from our facility in Stayner, Ontario (the "Stayner Facility") and the expected costs and benefits from the wind-down of the Stayner Facility;
- our ability to effectively wind-down the Stayner Facility in an organized fashion and acquire raw materials from other suppliers, including Cronos Growing Company Inc. ("Cronos GrowCo") and the costs and timing associated therewith;
- the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof;
- our international activities and joint venture interests, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact;
- our ability to successfully create and launch brands and further create, launch and scale U.S. hemp-derived cannabinoid consumer products and cannabis products;
- the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;
- expectations regarding the implementation and effectiveness of key personnel changes;
- the anticipated benefits and impact of Altria Group Inc.'s investment in the Company (the "Altria Investment"), pursuant to a subscription agreement dated December 7, 2018;
- the potential exercise of one warrant of the Company included as part of the Altria Investment (the "Altria Warrant"), pre-emptive rights and/or top-up rights in connection with the Altria Investment, including proceeds to us that may result therefrom;

- the impact of the loss of our ability to rely on private offering exemptions under Regulation D of the Securities Act of 1933, as amended (the “Securities Act”); and the loss of our status as a well-known seasoned issuer, each as a result of our settlement with the SEC (the “SEC Order”);
- our compliance with the terms of the SEC Order and the settlement with the Ontario Securities Commission (the “OSC Settlement”), including complying with any recommendations made by the independent consultant to be appointed pursuant to the SEC Order (the “Consultant”);
- expectations regarding the use of proceeds of equity financings, including the proceeds from the Altria Investment;
- the legalization of the use of cannabis for medical or adult-use in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if and when such use is legalized;
- expectations regarding the potential success of, and the costs and benefits associated with, our joint ventures, strategic alliances and equity investments, including the strategic partnership (the “Ginkgo Strategic Partnership”) with Ginkgo Bioworks Holdings, Inc. (“Ginkgo”);
- our ability to execute on our strategy and the anticipated benefits of such strategy;
- expectations of the amount or frequency of impairment losses, including as a result of the write-down of intangible assets, including goodwill;
- the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial, territorial and municipal regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such markets;
- the future performance of our business and operations;
- our competitive advantages and business strategies;
- the competitive conditions of the industry;
- the expected growth in the number of customers using our products;
- our ability or plans to identify, develop, commercialize or expand our technology and research and development (“R&D”) initiatives in cannabinoids, or the success thereof;
- expectations regarding acquisitions and dispositions and the anticipated benefits therefrom;
- uncertainties as to our ability to exercise our option (the “PharmaCann Option”) in PharmaCann Inc. (“PharmaCann”), in the near term or the future, in full or in part, including the uncertainties as to the status and future development of federal legalization of cannabis in the U.S. and our ability to realize the anticipated benefits of the transaction with PharmaCann;
- expectations regarding revenues, expenses and anticipated cash needs;
- expectations regarding cash flow, liquidity and sources of funding;
- expectations regarding capital expenditures;
- expectations regarding our future production and manufacturing strategy and operations, the costs and timing associated therewith and the receipt of applicable production and sale licenses;
- expectations regarding our growing, production and supply chain capacities;
- expectations regarding the resolution of litigation and other legal and regulatory proceedings, reviews and investigations;
- expectations with respect to future production costs;
- expectations with respect to future sales and distribution channels and networks;
- the expected methods to be used to distribute and sell our products;
- the anticipated future gross margins of our operations;
- accounting standards and estimates;
- our ability to timely and effectively remediate any material weaknesses in our internal control over financial reporting; and
- expectations regarding the costs and benefits associated with our contracts and agreements with third parties, including under our third-party supply and manufacturing agreements.

Certain of the Forward-Looking Statements contained herein concerning the industries in which we conduct our business are based on estimates prepared by us using data from publicly available governmental sources, market research, industry analysis and on assumptions based on data and knowledge of these industries, which we believe to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. The industries in which we conduct our business involve risks and uncertainties that are subject to change based on various factors, which are described further below.

The Forward-Looking Statements contained herein are based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including: (i) our ability to efficiently and effectively exit the Stayner Facility, receive the benefits of the Stayner Facility wind down and acquire raw materials on a timely and cost-effective basis from third parties, including Cronos GrowCo; (ii) our ability, and the abilities of our joint ventures and our suppliers and distributors, to effectively deal with the restrictions, limitations and health issues presented by the COVID-19 pandemic and the ability to continue our production, distribution and sale of our products and customer demand for and use of our products; (iii) management's perceptions of historical trends, current conditions and expected future developments; (iv) our ability to generate cash flow from operations; (v) general economic, financial market, regulatory and political conditions in which we operate; (vi) the production and manufacturing capabilities and output from our facilities and our joint ventures, strategic alliances and equity investments; (vii) consumer interest in our products; (viii) competition; (ix) anticipated and unanticipated costs; (x) government regulation of our activities and products including, but not limited to, the areas of taxation and environmental protection; (xi) the timely receipt of any required regulatory authorizations, approvals, consents, permits and/or licenses; (xii) our ability to obtain qualified staff, equipment and services in a timely and cost-efficient manner; (xiii) our ability to conduct operations in a safe, efficient and effective manner; (xiv) our ability to realize anticipated benefits, synergies or generate revenue, profits or value from our acquisitions into our existing operations; (xv) our ability to realize the expected cost-savings, efficiencies and other benefits of our Realignment and employee turnover related thereto; (xvi) our ability to complete planned dispositions, and, if completed, obtain our anticipated sales price; (xvii) our ability to exercise the PharmaCann Option and realize the anticipated benefits of the transaction with PharmaCann; and (xviii) other considerations that management believes to be appropriate in the circumstances. While our management considers these assumptions to be reasonable based on information currently available to management, there is no assurance that such expectations will prove to be correct.

By their nature, Forward-Looking Statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the Forward-Looking Statements in this Quarterly Report and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf. Such factors include, without limitation, that we may not be able to exit the Stayner Facility in an organized fashion or achieve the anticipated benefits of the exit or be able to access raw materials on a timely and cost-effective basis from third parties, including Cronos GrowCo; the risk that the COVID-19 pandemic and the military conflict between Russia and Ukraine may disrupt our operations and those of our suppliers and distribution channels and negatively impact the demand for and use of our products; the risk that cost savings and any other synergies from the Altria Investment may not be fully realized or may take longer to realize than expected; the risk that we will not complete planned dispositions, or, if completed, obtain our anticipated sales price; the implementation and effectiveness of key personnel changes; the risks that our Realignment, the closure of the Stayner Facility and our further leveraging of our strategic partnerships will not result in the expected cost-savings, efficiencies and other benefits or will result in greater than anticipated turnover in personnel; future levels of revenues; consumer demand for cannabis and U.S. hemp products; our ability to manage disruptions in credit markets or changes to our credit ratings; future levels of capital, environmental or maintenance expenditures, general and administrative and other expenses; the success or timing of completion of ongoing or anticipated capital or maintenance projects; business strategies, growth opportunities and expected investment; the adequacy of our capital resources and liquidity, including but not limited to, availability of sufficient cash flow to execute our business plan (either within the expected timeframe or at all); our ability to raise capital under Regulation D under the Securities Act and to qualify as a well-known seasoned issuer; the potential effects of judicial, regulatory or other proceedings, or threatened litigation or proceedings, on our business, financial condition, results of operations and cash flows; volatility in and/or degradation of general economic, market, industry or business conditions; compliance with applicable environmental, economic, health and safety, energy and other policies and regulations and in particular health concerns with respect to vaping and the use of cannabis and U.S. hemp products in vaping devices; the anticipated effects of actions of third parties such as competitors, activist investors or federal (including U.S. federal), state, provincial, territorial or local regulatory authorities or self-regulatory organizations; changes in regulatory requirements in relation to our business and products; legal or regulatory obstacles that could prevent us from being able to exercise the PharmaCann Option and thereby realizing the anticipated benefits of the transaction with PharmaCann; dilution of our fully-diluted ownership of PharmaCann and the loss of our rights as a result of that dilution; our remediation of material weaknesses in our internal control over financial reporting and the improvement of our control environment and our systems, processes and procedures; and the factors discussed under Part I, Item 1A "Risk Factors" of the Annual Report. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on Forward-Looking Statements.

Forward-Looking Statements are provided for the purposes of assisting the reader in understanding our financial performance, financial position and cash flows as of and for periods ended on certain dates and to present information about management's current expectations and plans relating to the future, and the reader is cautioned not to place undue reliance on these Forward-Looking Statements because of their inherent uncertainty and to appreciate the limited purposes for which they are being used by management. While we believe that the assumptions and expectations reflected in the Forward-Looking Statements are reasonable based on information currently available to management, there is no assurance that such assumptions and expectations will prove to have been correct. Forward-Looking Statements are made as of the date they are made and are based on the beliefs, estimates, expectations and opinions of management on that date. We undertake no obligation to update or revise any Forward-Looking Statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such Forward-Looking Statements. The Forward-Looking Statements contained in this Quarterly Report

and other reports we file with, or furnish to, the SEC and other regulatory agencies and made by our directors, officers, other employees and other persons authorized to speak on our behalf are expressly qualified in their entirety by these cautionary statements.

### Foreign currency exchange rates

All currency amounts in this Quarterly Report are stated in U.S. dollars, which is our reporting currency, unless otherwise noted. All references to “dollars” or “\$” are to U.S. dollars. The assets and liabilities of our foreign operations are translated into dollars at the exchange rate in effect as of September 30, 2022, September 30, 2021 and December 31, 2021. Transactions affecting the shareholders’ equity (deficit) are translated at historical foreign exchange rates. The condensed consolidated statements of net income (loss) and comprehensive income (loss) and condensed consolidated statements of cash flows of our foreign operations are translated into dollars by applying the average foreign exchange rate in effect for the reporting period as reported on Bloomberg.

The exchange rates used to translate from Canadian dollars (“C\$”) to dollars is shown below:

*(Exchange rates are shown as C\$ per \$)*

	As of		
	September 30, 2022	September 30, 2021	December 31, 2021
Quarter-to-date average rate	1.3053	1.2593	N/A
Spot rate	1.3829	1.2680	1.2746
Year-to-date average rate	1.2829	1.2519	1.2541

### Business Overview

Cronos Group is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development and are seeking to build an iconic brand portfolio. Cronos Group’s diverse international brand portfolio includes Spinach<sup>®</sup>, PEACE NATURALS<sup>®</sup>, Lord Jones<sup>®</sup>, Happy Dance<sup>®</sup> and PEACE+<sup>®</sup>.

#### Strategy

Cronos Group seeks to create value for shareholders by focusing on four core strategic priorities:

- growing a portfolio of iconic brands that responsibly elevate the consumer experience;
- developing a diversified global sales and distribution network;
- establishing an efficient global supply chain; and
- creating and monetizing disruptive intellectual property.

#### Business segments

We report through two segments: “United States” (the “U.S. segment”) and “Rest of World” (the “ROW segment”). These two segments represent the geographic regions in which we operate and the different product offerings within each geographic region.

The U.S. segment manufactures, markets and distributes U.S. hemp-derived supplements and cosmetic products through e-commerce, retail and hospitality partner channels in the United States under the brands Lord Jones<sup>®</sup>, Happy Dance<sup>®</sup> and PEACE+<sup>®</sup>.

The ROW segment is involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. In Canada, Cronos Group operates two wholly owned license holders under the Cannabis Act (Canada) (the “Cannabis Act”), Peace Naturals Project Inc. (“Peace Naturals”), which has production facilities near Stayner, Ontario (the “Stayner Facility”), and Thanos Holdings Ltd., known as Cronos Fermentation (“Cronos Fermentation”), which has a production facility in Winnipeg, Manitoba. In Israel, the Company operates under the IMC-GAP, IMC-GMP and IMC-GDP certifications required for the cultivation, production and marketing of dried flower, pre-rolls and cannabis oils in the Israeli medical market. Cronos Group has established three strategic joint ventures in Canada, Israel and Colombia. Additionally, as of September 30, 2022, Cronos Group held approximately 10% of the issued capital of Cronos Australia Limited (“Cronos Australia”), which is listed on the Australian Securities Exchange under the trading symbol “CAU.”

## Recent Developments

### *COVID-19 update*

In December 2019, an outbreak of a novel strain of coronavirus, COVID-19, was identified in Wuhan, China. Since then, COVID-19 has spread across the globe, including the U.S., Canada and Israel, and other countries in which Cronos Group or its affiliates operate (including Australia and Colombia) and was recognized as a pandemic by the World Health Organization. The COVID-19 pandemic resulted in a sharp contraction in many areas of the global economy and increased volatility and uncertainty in the capital markets. In response to the pandemic, the governments of many countries, provinces, states, municipalities, and other geographic regions took preventative or protective actions, including closures of certain businesses, mandatory quarantines, limits on individuals' time outside of their homes, travel restrictions and social distancing or other preventative measures. Such measures were eased or lifted in varying degrees by different governments of various countries, states and municipalities since implementation in 2020, but the continued spread of COVID-19 and increased infection rates has caused, and may continue to cause, some jurisdictions to roll back reopening plans that had been underway and re-impose quarantines, border closures, closure of certain businesses and stay-at-home orders.

The COVID-19 pandemic continues to impact the global economy and, specifically, the U.S., Canada, Israel, and the other countries in which Cronos Group or its affiliates operate (including Australia and Colombia). We continue to closely monitor and respond, where possible, to the ongoing COVID-19 pandemic. As the global situation continues to change rapidly, ensuring the health and safety of our employees remains one of our top priorities.

In the U.S., numerous states have continued to remove their COVID-19 related restrictions. This has resulted in the re-opening of, and increased occupancy capacities in, retail outlets, including those that sell our products. Any reinstatement of restrictions on the operations of retail outlets could negatively impact our short-term results of operations in the U.S. Recently in the U.S., there have been a number of supply chain challenges, such as container ships facing delays due to congestion in ports, impacting many industries, including the industries in which we operate. Although we have not yet seen a significant impact from supply chain disruptions, we continue to monitor our supply chain closely.

In Canada, COVID-19 restrictions began gradually easing at the end of June 2021 as the vaccination rate increased. The lockdown measures taken in the first six months of 2021 to slow infection rates negatively impacted our short-term revenue growth in Canada in 2021. The increase in cases related to the Omicron variant of COVID-19 beginning in December 2021 caused the reinstatement of some restrictions on non-essential retail stores in some provinces, including Quebec, in early 2022; however, those restrictions have eased in most other provinces. Each province is responsible for implementing re-opening plans and certain provinces, including Ontario, are progressing through phases of re-opening which may permit continued increases to the allowance of in-person shopping, typically in the form of percentage of store capacity. All provinces have some form of cannabis retail open to consumers, and most provinces have lifted the requirement that retail shoppers show proof of vaccination before entering retail stores. The potential for recurring retail restrictions is ongoing, which could negatively impact our results of operations.

In Israel, most COVID-19 restrictions have been removed as vaccination rates have increased. Occupancy limitations in retail outlets have been removed, including those that sell our products. We do not expect the remaining COVID-19 restrictions to have a material impact on our short-term revenue growth in Israel.

Collectively, the effects of the COVID-19 pandemic have adversely affected our results of operations and, if the effects continue unabated, could continue to do so as long as measures to combat the COVID-19 pandemic remain in effect or supply chains continue to be challenged. At this time, neither the duration nor scope of the disruption can be predicted; therefore, the ultimate impact to our business cannot be reasonably estimated, but such impact could materially adversely affect our business, financial condition and results of operations.

Despite the impacts of the COVID-19 pandemic, we believe that our significant cash on hand and short-term investments will be adequate to meet liquidity and capital requirements for at least the next twelve months.

***Strategic and Organizational Update***

In the third quarter of 2022, following the decision to begin a phased exit of the wholesale beauty category in the U.S. business in the second quarter of 2022, the Company continued to reduce operating expenses in the U.S. to better align the business structure with the new strategy to focus on adult-use product formats in the direct-to-consumer channel.

Due to the restructuring of the U.S. business and other newly identified cost savings opportunities, the Company now expects to incur approximately \$6.1 million in expenses in connection with the Realignment, a decrease from the previously stated \$6.4 million.

The Company now anticipates exiting the Peace Naturals Campus in 2023 due to longer than anticipated transition timing for contract manufacturers, lead times on required equipment, and the receipt of necessary regulatory licenses. As the Company continues its transition out of the Peace Naturals Campus in Stayner, Ontario into 2023, it anticipates that it will begin to incur the majority of the expected capital expenditures related to the Realignment.

***Brand and Product Portfolio***

In the third quarter of 2022, Cronos Israel was awarded a prestigious Clio Award in the Social Good category for the PEACE NATURALS® brand campaign in partnership with the Warriors for Life Association in Israel.

In October 2022, the Company continued to expand its gummy offering with the launch of SOURZ by Spinach™ Tropical Triple Berry 2:1 CBD:THC. This marks Cronos' first CBD dominant edible in the Canadian adult-use market for those looking for a more mellow low-dose experience.

In November 2022, Cronos will launch two infused pre-rolls in Canada. The first, under the Spinach® brand is called Fully Charged Atomic GMO, which will be offered in a 5-pack with 0.5 grams per pre-roll. Secondly, Cronos is launching a CBG infused pre-roll under the Spinach FEELZ™ brand called Tropical Diesel CBG, which will be offered in a 3-pack with 0.5 grams per pre-roll.

## Consolidated Results of Operations

The tables below set forth our condensed consolidated results of operations, expressed in thousands of U.S. dollars for the periods presented. Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods.

	Three months ended September 30,		Nine months ended September 30,	
	2022	2021	2022	2021
Net revenue, before excise taxes	\$ 26,584	\$ 24,590	\$ 84,544	\$ 58,092
Excise taxes	(5,661)	(4,183)	(15,527)	(9,452)
Net revenue	20,923	20,407	69,017	48,640
Cost of sales	19,766	21,137	56,814	56,156
Inventory write-down	—	—	—	11,961
Gross profit	1,157	(730)	12,203	(19,477)
Operating expenses				
Sales and marketing	5,923	10,821	16,517	34,284
Research and development	2,569	6,473	10,910	16,774
General and administrative	17,167	32,546	56,540	76,869
Restructuring costs	524	—	4,878	—
Share-based compensation	4,265	2,667	10,567	7,731
Depreciation and amortization	1,713	1,251	4,417	3,029
Impairment loss on goodwill and indefinite-lived intangible assets	—	142	—	235,056
Impairment loss on long-lived assets	—	1,784	3,493	4,739
Total operating expenses	32,161	55,684	107,322	378,482
Operating loss	(31,004)	(56,414)	(95,119)	(397,959)
Other income (expense)	(3,764)	133,839	7,414	134,988
Income tax benefit (expense)	(2,118)	159	(2,172)	159
Income (loss) from discontinued operations	—	82	—	(500)
Net income (loss)	(36,886)	77,666	(89,877)	(263,312)
Net income (loss) attributable to non-controlling interest	105	(250)	(27)	(842)
Net income (loss) attributable to Cronos Group	\$ (36,991)	\$ 77,916	\$ (89,850)	\$ (262,470)

### Summary of select financial results

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2022	2021	\$	%	2022	2021	\$	%
Net revenue	\$ 20,923	\$ 20,407	\$ 516	3 %	\$ 69,017	\$ 48,640	\$ 20,377	42 %
Cost of sales	19,766	21,137	(1,371)	(6) %	56,814	56,156	658	1 %
Inventory write-down	—	—	—	N/A	—	11,961	(11,961)	(100) %
Gross profit	1,157	(730)	1,887	258 %	12,203	(19,477)	31,680	163 %
Gross margin <sup>(i)</sup>	6 %	(4) %	N/A	10 pp	18 %	(40) %	N/A	58 pp

<sup>(i)</sup> Gross margin is defined as gross profit divided by net revenue.

### Net revenue

For the three months ended September 30, 2022, we reported consolidated net revenue of \$20.9 million, representing an increase of \$0.5 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, we reported consolidated net revenue of \$69.0 million, representing an increase of \$20.4 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the increase was primarily due to higher cannabis flower sales in the Israeli medical market and higher cannabis extract sales in the Canadian adult-use market, partially offset by a reduction in revenue in the U.S. segment, lower cannabis flower sales in the Canadian adult-use market driven by an adverse price/mix shift and the impact of the weakening Canadian dollar against the U.S. dollar during the current period.

### Cost of sales

For the three months ended September 30, 2022, we reported consolidated cost of sales of \$19.8 million, representing a decrease of \$1.4 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, we reported consolidated cost of sales of \$56.8 million, representing an increase of approximately \$0.7 million from the nine months ended September 30, 2021. For the three-month comparative period, the decrease was primarily due to lower cannabis biomass costs, lower sales volumes in the U.S. segment and the impact of the weakening Canadian dollar against the U.S. dollar during the current period, partially offset by higher sales volumes in the ROW segment and lower fixed cost absorption due to the timing of wind down activities associated with our planned exit of the Stayner Facility. For the nine-month comparative period, the increase was primarily due to higher sales volumes in the ROW segment and lower fixed cost absorption due to the timing of wind down activities associated with our planned exit of the Stayner facility, partially offset by lower cannabis biomass costs, lower sales volumes in the U.S. segment and the impact of the weakening Canadian dollar against the U.S. dollar during the period.

### Inventory write-down

For the nine months ended September 30, 2021, we reported inventory write-downs of \$12.0 million primarily related to cannabis strains and potency levels that were no longer in-line with consumer preferences in the Canadian market and adjustments for obsolete inventory in Canada. We reported no such write-down for the three months ended September 30, 2021 and for the three and nine months ended September 30, 2022.

### Gross profit

For the three months ended September 30, 2022, we reported gross profit of \$1.2 million, representing an increase in gross profit of \$1.9 million compared to the three months ended September 30, 2021. For the nine months ended September 30, 2022, we reported gross profit of \$12.2 million, representing an increase in gross profit of \$31.7 million compared to the nine months ended September 30, 2021. For the three-month comparative period, the change was primarily due to increased revenue in the ROW segment driven mainly by sales of cannabis flower in Israel and a favorable mix of cannabis extract products, which carry a higher gross profit and gross margin than other product categories, and lower cannabis biomass costs, partially offset by lower fixed cost absorption due to the timing of wind-down activities associated with our planned exit of the Stayner Facility and lower revenue in the U.S. segment. For the nine-month comparative period, the change was primarily due to increased revenue in the ROW segment driven mainly by sales of cannabis flower in Israel and a favorable mix of cannabis extract products, which carry a higher gross profit and gross margin than other product categories, the absence of inventory write-downs in the current period, and lower cannabis biomass costs, partially offset by lower fixed cost absorption due to the timing of wind-down activities associated with our planned exit of the Stayner Facility and lower revenue in the U.S. segment.

### Operating expenses

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2022	2021	\$	%	2022	2021	\$	%
Sales and marketing	\$ 5,923	\$ 10,821	\$ (4,898)	(45)%	\$ 16,517	\$ 34,284	\$ (17,767)	(52)%
Research and development	2,569	6,473	(3,904)	(60)%	10,910	16,774	(5,864)	(35)%
General and administrative	17,167	32,546	(15,379)	(47)%	56,540	76,869	(20,329)	(26)%
Restructuring costs	524	—	524	N/A	4,878	—	4,878	N/A
Share-based compensation	4,265	2,667	1,598	60 %	10,567	7,731	2,836	37 %
Depreciation and amortization	1,713	1,251	462	37 %	4,417	3,029	1,388	46 %
Impairment loss on goodwill and indefinite-lived intangible assets	—	142	(142)	(100)%	—	235,056	(235,056)	(100)%
Impairment loss on long-lived assets	—	1,784	(1,784)	(100)%	3,493	4,739	(1,246)	(26)%
Total operating expenses	\$ 32,161	\$ 55,684	\$ (23,523)	(42)%	\$ 107,322	\$ 378,482	\$ (271,160)	(72)%

### Sales and marketing

For the three months ended September 30, 2022, sales and marketing expenses were \$5.9 million, representing a decrease of \$4.9 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, sales and marketing expenses were \$16.5 million, representing a decrease of \$17.8 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the decrease was primarily due to lower advertising and marketing spend and lower payroll-related costs in the U.S. segment as a result of the Realignment.

#### *Research and development*

For the three months ended September 30, 2022, research and development expenses were \$2.6 million, representing a decrease of \$3.9 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, research and development expenses were \$10.9 million, representing a decrease of \$5.9 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the decrease was primarily due to lower costs associated with the timing of Ginkgo milestones and a cancellation of beauty-focused product development spending in the U.S. segment.

#### *General and administrative*

For the three months ended September 30, 2022, general and administrative expenses were \$17.2 million, representing a decrease of \$15.4 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, general and administrative expenses were \$56.5 million, representing a decrease of \$20.3 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the decrease was primarily due to credit loss revaluation allowances recognized in the prior comparative period and reduced advisory fees associated with strategic initiatives.

#### *Restructuring costs*

For the three and nine months ended September 30, 2022, restructuring costs were \$0.5 million and \$4.9 million, respectively, compared to no restructuring costs for the three and nine months ended September 30, 2021. Restructuring costs for both the three and nine months ended September 30, 2022, were related to the Realignment, including the planned exit of the Stayner Facility.

#### *Share-based compensation*

For the three months ended September 30, 2022, share-based compensation expense was \$4.3 million, representing an increase of \$1.6 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, share-based compensation expense was \$10.6 million, representing an increase of \$2.8 million from the nine months ended September 30, 2021. For the three-month comparative periods, the increase was primarily due to previously held-back equity awards granted to certain executives in the three months ended September 30, 2022. For the nine-month comparative periods, the increase was primarily due to the acceleration of expense on equity awards granted to certain executive employees in connection with their separation from the Company, as well as previously held-back equity awards granted to certain executives in the nine months ended September 30, 2022.

#### *Depreciation and amortization*

For the three months ended September 30, 2022, depreciation and amortization expenses were \$1.7 million, representing an increase of \$0.5 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, depreciation and amortization expenses were \$4.4 million, representing an increase of \$1.4 million from the nine months ended September 30, 2021. For the three- and nine-month comparative periods, the increase was primarily due to higher amortization on Ginkgo-related intangible assets.

#### *Impairment loss on goodwill and indefinite-lived intangible assets*

For both the three and nine month ended September 30, 2022, there was no impairment loss on goodwill and indefinite-lived intangible assets. For both the three and nine month ended September 30, 2021, impairment loss on goodwill and indefinite-lived intangible assets was \$0.1 million and \$235.1 million, respectively. The impairment loss on goodwill and indefinite-lived intangible assets in the nine months ended September 30, 2021 was due to impairment charges on the goodwill associated with our U.S. reporting unit and Lord Jones® brand.

#### *Impairment loss on long-lived assets*

For the three months ended September 30, 2022, there was no impairment loss on long-lived assets compared to \$1.8 million impairment loss from the three months ended September 30, 2021. For the nine months ended September 30, 2022, impairment loss on long-lived assets was \$3.5 million, representing a decrease of \$1.2 million from the nine months ended September 30, 2021. For further information, see Note 13 “*Impairment Loss on Long-lived Assets*” to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

**Other income (loss), income tax expense and discontinued operations**

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2022	2021	\$	%	2022	2021	\$	%
Interest income, net	\$ 7,209	\$ 2,064	\$ 5,145	249 %	\$ 13,030	\$ 6,686	\$ 6,344	95 %
Gain on revaluation of derivative liabilities	375	132,916	(132,541)	(100)%	14,204	131,290	(117,086)	(89)%
Share of income (loss) from equity method investments	(1,119)	(1,414)	295	21 %	4,078	(4,172)	8,250	198 %
Gain on revaluation of financial instruments	17,049	266	16,783	N/M	19,205	143	19,062	N/M
Impairment loss on other investments	(28,972)	—	(28,972)	N/A	(40,210)	—	(40,210)	N/A
Foreign currency transaction gain (loss)	2,387	—	2,387	N/A	(2,337)	—	(2,337)	N/A
Other, net	(693)	7	(700)	N/M	(556)	1,041	(1,597)	(153)%
Total other income	(3,764)	133,839	(137,603)	(103)%	7,414	134,988	(127,574)	(95)%
Income tax benefit (expense)	(2,118)	159	(2,277)	N/A	(2,172)	159	(2,331)	N/A
Income (loss) from discontinued operations	—	82	(82)	(100)%	—	(500)	500	100 %
Net income (loss)	\$ (36,886)	\$ 77,666	\$ (114,552)	(147)%	\$ (89,877)	\$ (263,312)	\$ 173,435	66 %

<sup>(i)</sup> “N/M” is defined as not meaningful.

**Interest income, net**

For the three months ended September 30, 2022, interest income, net was \$7.2 million, representing an increase of \$5.1 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, interest income, net was \$13.0 million, representing an increase of \$6.3 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the increase in net interest income was primarily due to higher short-term investment balances and higher interest rates during the current period.

**Gain on revaluation of derivative liabilities**

For the three months ended September 30, 2022, the gain on revaluation of derivative liabilities was \$0.4 million, representing a decrease of \$132.5 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, the gain on revaluation of derivative liabilities was \$14.2 million, representing a decrease of \$117.1 million from the nine months ended September 30, 2021. We expect continued changes in derivative valuations as our share price fluctuates period to period and the remaining expected terms of our derivative instruments decrease. For further information, see Note 6 “Derivative Liabilities” to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

**Share of income (loss) from equity method investments**

For the three months ended September 30, 2022, our share of loss from equity method investments was \$1.1 million, representing a decrease of \$0.3 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, our share of income from equity method investments was \$4.1 million, representing an increase of \$8.3 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the change was due to improved results from our equity method investment in Cronos GrowCo.

**Gain on revaluation of financial instruments**

For the three months ended September 30, 2022, the gain on revaluation of financial instruments was \$17.0 million, representing an increased gain of \$16.8 million compared to the three months ended September 30, 2021. For the nine months ended September 30, 2022, the gain on revaluation of financial instruments was \$19.2 million, representing an increased gain of \$19.1 million compared to the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the change was primarily related to the change in fair value of our investment in Cronos Australia. For further information, see Note 3 “Investments” to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

### Impairment loss on other investments

For the three and nine months ended September 30, 2022, impairment loss on other investments was \$29.0 million and \$40.2 million, respectively, driven by impairments of the PharmaCann Option for the difference between its estimated fair value and its carrying amount. There were no impairment losses on other investments during the three and nine months ended September 30, 2021. For more information, see Note 3 “Investments” in our condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

### Foreign currency transaction gain (loss)

For the three and nine months ended September 30, 2022, foreign currency transaction gain (loss) was \$2.4 million and \$(2.3) million, respectively, which related to certain foreign currency-denominated intercompany loans anticipated to be settled in the foreseeable future. There were no such foreign currency transaction gains or losses during the three and nine months ended September 30, 2021.

### Other, net

For the three months ended September 30, 2022, other, net was a loss of \$0.7 million, compared to breakeven for the three months ended September 30, 2021. For the nine months ended September 30, 2022, other, net was a loss of \$0.6 million, compared to income of \$1.0 million in the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the change was due to loss on disposal of assets associated with the Realignment, partially offset by dividend income from our Cronos Australia investment during the current periods.

## Results of Operations by Business Segment:

The tables below set forth our condensed consolidated results of operations by our two business segments: the ROW segment and the U.S. segment, expressed in U.S. dollars and in thousands for the periods presented. Our condensed consolidated financial results for these periods are not necessarily indicative of the consolidated financial results that we will achieve in future periods. Certain totals in the tables below will not sum to exactly 100% due to rounding.

### Summary of select financial results – ROW

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2022	2021	\$	%	2022	2021	\$	%
Net revenue	\$ 20,409	\$ 18,307	\$ 2,102	11 %	\$ 64,716	\$ 41,872	\$ 22,844	55 %
Cost of sales	17,265	17,735	(470)	(3) %	50,540	49,906	634	1 %
Inventory write-down	—	—	—	N/A	—	11,961	(11,961)	(100) %
Gross profit	3,144	572	2,572	450 %	14,176	(19,995)	34,171	171 %
Gross margin	15 %	3 %	N/A	12 pp	22 %	(48) %	N/A	70 pp

### Net revenue – ROW

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2022	2021	\$	%	2022	2021	\$	%
Cannabis flower	\$ 13,674	\$ 15,306	\$ (1,632)	(11) %	\$ 48,038	\$ 36,337	\$ 11,701	32 %
Cannabis extracts	6,627	2,786	3,841	138 %	16,197	5,020	11,177	223 %
Other	108	215	(107)	(50) %	481	515	(34)	(7) %
Net revenue	\$ 20,409	\$ 18,307	\$ 2,102	11 %	\$ 64,716	\$ 41,872	\$ 22,844	55 %

For the three months ended September 30, 2022, the ROW segment reported net revenue of \$20.4 million, representing an increase of \$2.1 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, the ROW segment reported net revenue of \$64.7 million, representing an increase of \$22.8 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the change was primarily due to higher cannabis flower sales in the Israeli medical market and higher cannabis extract sales in the Canadian adult-use market, partially offset by lower cannabis flower sales in the Canadian adult-use market driven by an adverse price/mix shift and the impact of the weakening Canadian dollar against the U.S. dollar during the period.

### Cost of sales – ROW

For the three months ended September 30, 2022, the ROW segment reported cost of sales of \$17.3 million, representing a decrease of \$0.5 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, the ROW segment reported cost of sales of \$50.5 million, representing an increase of \$0.6 million from the nine months ended September 30, 2021. For

the three-month comparative period, the decrease was primarily due to lower cannabis biomass costs and the impact of the weakening Canadian dollar against the U.S. dollar during the current period, partially offset by higher sales volumes and lower fixed cost absorption due to the timing of wind down activities associated with our planned exit of the Stayner Facility. For the nine-month comparative period, the increase was primarily due to higher sales volumes and lower fixed cost absorption due to the timing of wind down activities associated with our planned exit of the Stayner Facility, partially offset by lower cannabis biomass costs and the impact of the weakening Canadian dollar against the U.S. dollar during the current period.

#### ***Inventory write-down – ROW***

For the nine months ended September 30, 2021, the ROW segment reported consolidated inventory write-down of \$12.0 million primarily related to cannabis strains and potency levels that were no longer in-line with consumer preferences in the Canadian market and adjustments for obsolete inventory in Canada. The ROW segment reported no such write-down for the three months ended September 30, 2021 and the three and nine months ended September 30, 2022.

#### ***Gross profit – ROW***

For the three months ended September 30, 2022, the ROW segment reported gross profit of \$3.1 million, representing an increase in gross profit of \$2.6 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, the ROW segment reported gross profit of \$14.2 million, representing an increase in gross profit of \$34.2 million from the nine months ended September 30, 2021. For the three-month comparative period, the change was primarily due to increased revenue driven mainly by sales of cannabis flower in Israel and a higher cannabis extract sales in Canada, which carry a higher gross profit and gross margin than other product categories, and lower cannabis biomass costs, partially offset by lower fixed cost absorption due to the timing of wind-down activities associated with our planned exit of the Stayner Facility. For the nine-month comparative period, the change was primarily due to the absence of inventory write-downs in the current periods, increased revenue driven mainly by sales of cannabis flower and a favorable mix of cannabis extract products, which carry a higher gross profit and gross margin than other product categories, and lower cannabis biomass costs, partially offset by lower fixed cost absorption due to the timing of wind-down activities associated with our planned exit of the Stayner Facility.

#### ***Summary of select financial results – U.S.***

	Three months ended September 30,		Change		Nine months ended September 30,		Change	
	2022	2021	\$	%	2022	2021	\$	%
Net revenue	\$ 514	\$ 2,100	\$ (1,586)	(76) %	\$ 4,301	\$ 6,768	\$ (2,467)	(36) %
Cost of sales	2,501	3,402	(901)	(26) %	6,274	6,250	24	— %
Gross profit	(1,987)	(1,302)	(685)	(53) %	(1,973)	518	(2,491)	(481) %
Gross margin	(387)%	(62)%	N/A	(325)pp	(46)%	8 %	N/A	(54)pp

#### ***Net revenue – U.S.***

For the three months ended September 30, 2022, the U.S. segment reported net revenue of \$0.5 million, representing a decrease of \$1.6 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, the U.S. segment reported net revenue of \$4.3 million, representing a decrease of \$2.5 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the decrease was primarily driven by a reduction in sales as a result of a decrease in promotional spending and SKU rationalization efforts as the Company implements the Realignment in the U.S. segment.

#### ***Cost of sales – U.S.***

For the three months ended September 30, 2022, the U.S. segment reported cost of sales of \$2.5 million, representing a decrease of \$0.9 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, the U.S. segment reported cost of sales of \$6.3 million, essentially unchanged from the nine months ended September 30, 2021. For the three-month comparative period, the decrease was primarily due to lower sales volumes. For the nine-month comparative period, the reduction in cost of sales was driven by lower sales volumes, partially offset by a higher level of inventory reserves.

#### ***Gross profit – U.S.***

For the three months ended September 30, 2022, the U.S. segment reported gross profit of \$(2.0) million, representing a decrease of \$0.7 million from the three months ended September 30, 2021. For the nine months ended September 30, 2022, the U.S. segment reported gross profit of \$(2.0) million, representing a decrease of \$2.5 million from the nine months ended September 30, 2021. For both the three- and nine-month comparative periods, the change was primarily due to lower sales volumes and higher inventory reserves.

## Non-GAAP Measures

Cronos Group reports its financial results in accordance with Generally Accepted Accounting Principles in the United States (“U.S. GAAP”). This Quarterly Report refers to measures not recognized under U.S. GAAP (“non-GAAP measures”). These non-GAAP measures do not have a standardized meaning prescribed by U.S. GAAP and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these non-GAAP measures are provided as a supplement to corresponding U.S. GAAP measures to provide additional information regarding the results of operations from management’s perspective. Accordingly, non-GAAP measures should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with U.S. GAAP. All non-GAAP measures presented in this Quarterly Report are reconciled to their closest reported U.S. GAAP measure. Reconciliations of historical adjusted financial measures to corresponding U.S. GAAP measures are provided below.

### Adjusted EBITDA

Management reviews Adjusted EBITDA, a non-GAAP measure, which excludes non-cash items and items that do not reflect management’s assessment of ongoing business performance of our operating segments. Management defines Adjusted EBITDA as net income (loss) before interest, tax expense (benefit), depreciation and amortization adjusted for: share of income (loss) from equity method investments; impairment loss on goodwill and intangible assets; impairment loss on long-lived assets; (gain) loss on revaluation of derivative liabilities; (gain) loss on revaluation of financial instruments; transaction costs related to strategic projects; impairment loss on other investments; foreign currency transaction loss; other, net; loss from discontinued operations; restructuring costs; share-based compensation; and financial statement review costs and reserves related to the restatements of our 2019 and 2021 interim financial statements (the “Restatements”), including the costs related to the settlement of the SEC’s and the OSC’s investigations of the Restatements and legal costs defending shareholder class action complaints brought against us as a result of the 2019 restatement (see Part II, Item 1 “Legal Proceedings” of this Quarterly Report for a discussion of the shareholder class action complaints relating to the restatement of the 2019 interim financial statements and the settlement of the SEC’s and the OSC’s investigations of the Restatements).

Management believes that Adjusted EBITDA provides the most useful insight into underlying business trends and results and provides a more meaningful comparison of period-over-period results. Management uses Adjusted EBITDA for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets.

Adjusted EBITDA is reconciled to net income (loss) as follows:

(In thousands of U.S. dollars)

	Three months ended September 30, 2022			
	United States	Rest of World	Corporate	Total
Net income (loss)	\$ (33,223)	\$ 2,817	\$ (6,480)	\$ (36,886)
Interest income, net	(1,418)	(5,791)	—	(7,209)
Income tax expense	—	2,118	—	2,118
Share of loss from equity method investments	—	1,119	—	1,119
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(375)	—	(375)
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(17,049)	—	(17,049)
Impairment loss on other investment <sup>(vi)</sup>	28,972	—	—	28,972
Foreign currency transaction gain	—	(2,387)	—	(2,387)
Other, net <sup>(vii)</sup>	159	534	—	693
Restructuring costs <sup>(ix)</sup>	137	387	—	524
Share-based compensation <sup>(x)</sup>	8	4,257	—	4,265
Financial statement review costs <sup>(xi)</sup>	—	—	1,070	1,070
Depreciation and amortization	501	2,947	—	3,448
Adjusted EBITDA	\$ (4,864)	\$ (11,423)	\$ (5,410)	\$ (21,697)

(In thousands of U.S. dollars)

	Three months ended September 30, 2021			
	United States	Rest of World	Corporate	Total
Net income (loss)	\$ (13,499)	\$ 97,198	\$ (6,033)	\$ 77,666
Interest income, net	(4)	(2,060)	—	(2,064)
Income tax benefit	—	(159)	—	(159)
Share of loss from equity method investments	—	1,414	—	1,414
Impairment loss on goodwill and indefinite-lived intangible assets <sup>(i)</sup>	105	37	—	142
Impairment loss on long-lived assets <sup>(ii)</sup>	—	1,784	—	1,784
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(132,916)	—	(132,916)
Transaction costs <sup>(iv)</sup>	—	—	542	542
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(266)	—	(266)
Other, net <sup>(vii)</sup>	—	(7)	—	(7)
Income from discontinued operations <sup>(viii)</sup>	—	(82)	—	(82)
Share-based compensation <sup>(x)</sup>	967	1,700	—	2,667
Financial statement review costs <sup>(xi)</sup>	—	—	678	678
Depreciation and amortization	231	3,597	—	3,828
Adjusted EBITDA	\$ (12,200)	\$ (29,760)	\$ (4,813)	\$ (46,773)

(In thousands of U.S. dollars)

	Nine months ended September 30, 2022			
	United States	Rest of World	Corporate	Total
Net loss	\$ (59,937)	\$ (3,928)	\$ (26,012)	\$ (89,877)
Interest income, net	(1,873)	(11,157)	—	(13,030)
Income tax expense	—	2,172	—	2,172
Share of income from equity method investments	—	(4,078)	—	(4,078)
Impairment loss on long-lived assets <sup>(ii)</sup>	—	3,493	—	3,493
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(14,204)	—	(14,204)
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(19,205)	—	(19,205)
Impairment loss on other investment <sup>(vi)</sup>	40,210	—	—	40,210
Foreign currency transaction loss	—	2,337	—	2,337
Other, net <sup>(vii)</sup>	159	397	—	556
Restructuring costs <sup>(ix)</sup>	1,482	3,396	—	4,878
Share-based compensation <sup>(x)</sup>	2,917	7,650	—	10,567
Financial statement review costs <sup>(xi)</sup>	—	—	6,286	6,286
Depreciation and amortization	1,215	9,284	—	10,499
Adjusted EBITDA	\$ (15,827)	\$ (23,843)	\$ (19,726)	\$ (59,396)

(In thousands of U.S. dollars)

	Nine months ended September 30, 2021			
	United States	Rest of World	Corporate	Total
Net income (loss)	\$ (273,438)	\$ 34,678	\$ (24,552)	\$ (263,312)
Interest income, net	(27)	(6,659)	—	(6,686)
Income tax benefit	—	(159)	—	(159)
Share of loss from equity method investments	—	4,172	—	4,172
Impairment loss on goodwill and indefinite-lived intangible assets <sup>(i)</sup>	235,019	37	—	235,056
Impairment loss on long-lived assets <sup>(ii)</sup>	2,955	1,784	—	4,739
Gain on revaluation of derivative liabilities <sup>(iii)</sup>	—	(131,290)	—	(131,290)
Transaction costs <sup>(iv)</sup>	—	—	3,801	3,801
Gain on revaluation of financial instruments <sup>(v)</sup>	—	(143)	—	(143)
Other, net <sup>(vii)</sup>	—	(1,041)	—	(1,041)
Loss from discontinued operations <sup>(viii)</sup>	—	500	—	500
Share-based compensation <sup>(x)</sup>	2,534	5,197	—	7,731
Financial statement review costs <sup>(xi)</sup>	—	—	4,615	4,615
Depreciation and amortization	536	8,375	—	8,911
Adjusted EBITDA	\$ (32,421)	\$ (84,549)	\$ (16,136)	\$ (133,106)

<sup>(i)</sup> For the three and nine months ended September 30, 2021, impairment on goodwill and indefinite-lived intangible assets relates to impairment on goodwill and indefinite-lived intangible assets related to the Company's U.S. segment.

<sup>(ii)</sup> For the nine months ended September 30, 2022, impairment loss on long-lived assets related to the Company's decision to seek a sublease for leased office space in Toronto, Ontario, Canada during the first quarter of 2022. For the three months ended September 30, 2021, impairment loss on long-lived assets relates to an impairment on property, plant and equipment in the U.S. segment. For the nine months ended September 30, 2021, impairment loss on long-lived assets relates to the aforementioned impairment loss on property, plant and equipment as well as an impairment loss on leased premises in the U.S. segment from the first quarter of 2021. See Note 13 "Impairment Loss on Long-lived Assets" to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

<sup>(iii)</sup> For the three and nine months ended September 30, 2022 and 2021, gain on revaluation of derivative liabilities represents the fair value changes on the derivative liabilities. See Note 6 "Derivative Liabilities" to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

<sup>(iv)</sup> For the three and nine months ended September 30, 2021, transaction costs represent legal, financial and other advisory fees and expenses incurred in connection with various strategic investments. These costs are included in general and administrative expenses on the condensed consolidated statements of net income (loss) and comprehensive income (loss).

<sup>(v)</sup> For the three and nine months ended September 30, 2022, gain on revaluation of financial instruments related primarily to the Company's equity securities in Cronos Australia. See Note 3 "Investments" to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report. For three and nine months ended September 30, 2021, gain on revaluation of financial instruments related primarily to revaluations of financial liabilities resulting from DSUs.

<sup>(vi)</sup> For the nine months ended September 30, 2022, impairment loss on other investments related to the PharmaCann Option for the difference between its fair value and carrying amount. See Note 3 "Investments" to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

<sup>(vii)</sup> For the three months ended September 30, 2022, other, net related to \$1,083 loss on disposal of assets and \$390 of dividends declared by Cronos Australia on the Company's 55,176,065 ordinary shares in the capital of Cronos Australia. For the nine months ended September 30, 2022, other, net related to \$946 loss on disposal of assets and \$390 of dividends declared by Cronos Australia on the Company's 55,176,065 ordinary shares in the capital of Cronos Australia. For the three and nine months ended September 30, 2021, other, net primarily related to gain recorded on sale of an asset previously designated as held-for-sale in the first quarter of 2021.

<sup>(viii)</sup> For the three and nine months ended September 30, 2021, loss (income) from discontinued operations related to the discontinuance of OGBC.

<sup>(ix)</sup> For the three and nine months ended September 30, 2022, restructuring costs related to the employee-related severance costs and other restructuring costs associated with the Realignment, including the planned exit of the Stayner Facility. See Note 7 "Restructuring" to the condensed consolidated interim financial statements under Item 1 of this Quarterly Report.

<sup>(x)</sup> For the three and nine months ended September 30, 2022 and 2021, share-based compensation related to the vesting expenses of share-based compensation awarded to employees under the Company's share-based award plans as described in Note 8 "Share-based Compensation" to the condensed consolidated financial statements under Item 1 of this Quarterly Report.

<sup>(xi)</sup> For the three and nine months ended September 30, 2022 and 2021, financial statement review costs include costs and reserves taken related to the Restatements, costs related to the Company's settlement of the SEC's and the OSC's investigations of the Restatements and legal costs defending shareholder class action complaints brought against the Company as a result of the 2019 restatement.

### Constant Currency

To supplement the consolidated financial statements presented in accordance with U.S. GAAP, we have presented constant currency adjusted financial measures for net revenues, gross profit, gross profit margin, operating expenses, net income (loss) and Adjusted EBITDA for the three and nine months ended September 30, 2022 as well as cash and cash equivalents and short-term investment balances as of September 30, 2022 compared to December 31, 2021, which are considered non-GAAP financial measures. We present constant currency information to provide a framework for assessing how our underlying operations performed excluding the effect of foreign currency rate fluctuations. To present this information, current and comparative prior period income statement results in currencies other than U.S. dollars are converted into U.S. dollars using the average exchange rates from the three- and nine-month comparative periods in 2021 rather than the actual average exchange rates in effect during the respective current periods; constant currency current and prior comparative balance sheet information is translated at the prior year-end spot rate rather than the current period spot rate. All growth comparisons relate to the corresponding period in 2021. We have provided this non-GAAP financial information to aid investors in better understanding the performance of our segments. The non-GAAP financial measures presented in this Quarterly Report should not be considered as a substitute for, or superior to, the measures of financial performance prepared in accordance with U.S. GAAP.

The table below sets forth certain measures of consolidated results from continuing operations on a constant currency basis for the three and nine months ended September 30, 2022 compared to the three and nine months ended September 30, 2021 as well as cash and cash equivalents and short-term investments as of September 30, 2022 and December 31, 2021, both on an as-reported and constant currency basis (in thousands):

	As Reported				As Adjusted for Constant Currency			
	Three months ended September 30,		As Reported Change		Three months ended September 30,		Constant Currency Change	
	2022	2021	\$	%	2022	\$	%	
Net revenue	\$ 20,923	\$ 20,407	\$ 516	3 %	\$ 21,817	\$ 1,410	7 %	
Gross profit	1,157	(730)	1,887	258 %	1,341	2,071	284 %	
Gross margin	6 %	(4)%	N/A	10 pp	6 %	N/A	10 pp	
Operating expenses	32,161	55,684	(23,523)	(42) %	32,679	(23,005)	(41) %	
Net income (loss)	(36,886)	77,666	(114,552)	(147) %	(36,547)	(114,213)	(147) %	
Adjusted EBITDA	(21,697)	(46,773)	25,076	54 %	(22,008)	24,765	53 %	
	As Reported				As Adjusted for Constant Currency			
	Nine months ended September 30,		As Reported Change		Nine months ended September 30,		Constant Currency Change	
	2022	2021	\$	%	2022	\$	%	
Net revenue	\$ 69,017	\$ 48,640	\$ 20,377	42 %	\$ 70,426	\$ 21,786	45 %	
Gross profit	12,203	(19,477)	31,680	163 %	12,475	31,952	164 %	
Gross margin	18 %	(40)%	N/A	58 pp	18 %	N/A	58 pp	
Operating expenses	107,322	378,482	(271,160)	(72) %	108,736	(269,746)	(71) %	
Net loss	(89,877)	(263,312)	173,435	66 %	(89,934)	173,378	66 %	
Adjusted EBITDA	(59,396)	(133,106)	73,710	55 %	(59,917)	73,189	55 %	
	As of September 30,	As of December 31,	As Reported Change		As of September 30,	Constant Currency Change		
	2022	2021	\$	%	2022	\$	%	
	Cash and cash equivalents	\$ 633,296	\$ 886,973	\$ (253,677)	(29) %	\$ 660,084	\$ (226,889)	(26) %
Short-term investments	255,452	117,684	137,768	117 %	277,158	159,474	136 %	
Total cash and cash equivalents and short-term investments	\$ 888,748	\$ 1,004,657	\$ (115,909)	(12) %	\$ 937,242	\$ (67,415)	(7) %	

*Net revenue*

	As Reported				As Adjusted for Constant Currency			
	Three months ended September 30,		As Reported Change		Three months ended September 30,		Constant Currency Change	
	2022	2021	\$	%	2022	\$	%	
Cannabis flower	\$ 13,674	\$ 15,306	\$ (1,632)	(11)%	\$ 14,339	\$ (967)	(6)%	
Cannabis extracts	7,141	4,886	2,255	46 %	7,365	2,479	51 %	
Other	108	215	(107)	(50)%	113	(102)	(47)%	
Net revenue	\$ 20,923	\$ 20,407	\$ 516	3 %	\$ 21,817	\$ 1,410	7 %	

  

	As Reported				As Adjusted for Constant Currency			
	Nine months ended September 30,		As Reported Change		Nine months ended September 30,		Constant Currency Change	
	2022	2021	\$	%	2022	\$	%	
Cannabis flower	\$ 48,038	\$ 36,337	\$ 11,701	32 %	\$ 49,038	\$ 12,701	35 %	
Cannabis extracts	20,498	11,788	8,710	74 %	20,895	9,107	77 %	
Other	481	515	(34)	(7)%	493	(22)	(4)%	
Net revenue	\$ 69,017	\$ 48,640	\$ 20,377	42 %	\$ 70,426	\$ 21,786	45 %	

	As Reported				As Adjusted for Constant Currency			
	Three months ended September 30,		As Reported Change		Three months ended September 30,		Constant Currency Change	
	2022	2021	\$	%	2022	\$	%	
Canada	\$ 13,370	\$ 14,186	\$ (816)	(6)%	\$ 13,868	\$ (318)	(2)%	
Israel	7,039	3,752	3,287	88 %	7,435	3,683	98 %	
United States	514	2,100	(1,586)	(76)%	514	(1,586)	(76)%	
Other countries	—	369	(369)	(100)%	—	(369)	(100)%	
Net revenue	\$ 20,923	\$ 20,407	\$ 516	3 %	\$ 21,817	\$ 1,410	7 %	

  

	As Reported				As Adjusted for Constant Currency			
	Nine months ended September 30,		As Reported Change		Nine months ended September 30,		Constant Currency Change	
	2022	2021	\$	%	2022	\$	%	
Canada	\$ 41,335	\$ 32,432	\$ 8,903	27 %	\$ 42,358	\$ 9,926	31 %	
Israel	23,381	8,580	14,801	173 %	23,767	15,187	177 %	
United States	4,301	6,768	(2,467)	(36)%	4,301	(2,467)	(36)%	
Other countries	—	860	(860)	(100)%	—	(860)	(100)%	
Net revenue	\$ 69,017	\$ 48,640	\$ 20,377	42 %	\$ 70,426	\$ 21,786	45 %	

For the three months ended September 30, 2022, net revenue on a constant currency basis was \$21.8 million, representing a 7% increase from the three months ended September 30, 2021. For the nine months ended September 30, 2022, net revenue on a constant currency basis was \$70.4 million, representing a 45% increase from the nine months ended September 30, 2021. Net revenue increased for both the three and nine months ended September 30, 2022 on a constant currency basis and was primarily due to higher cannabis flower sales in the Israeli medical market and higher cannabis extract sales in the Canadian adult-use market, partially offset by a reduction in revenue in the U.S. segment and lower cannabis flower sales in the Canadian adult-use market driven by an adverse price/mix shift.

### Gross profit

For the three months ended September 30, 2022, gross profit on a constant currency basis was \$1.3 million, representing a 284% increase from the three months ended September 30, 2021. For the nine months ended September 30, 2022, gross profit on a constant currency basis was \$12.5 million, representing a 164% increase from the nine months ended September 30, 2021. For the three-month comparative period, the change was primarily due to increased revenue in the ROW segment driven mainly by sales of cannabis flower in Israel and a favorable mix of cannabis extract products, which carry a higher gross profit and gross margin than other product categories, and lower cannabis biomass costs, partially offset by lower fixed cost absorption due to the timing of wind-down activities associated with our planned exit of the Stayner Facility and lower revenue in the U.S. segment. For the nine-month comparative period, the change was primarily due to increased revenue in the ROW segment driven mainly by sales of cannabis flower in Israel and a favorable mix of cannabis extract products, which carry a higher gross profit and gross margin than other product categories, the absence of inventory write-downs in the current period, and lower cannabis biomass costs, partially offset by lower fixed cost absorption due to the timing of wind-down activities associated with our planned exit of the Stayner Facility and lower revenue in the U.S. segment.

### Operating expenses

For the three months ended September 30, 2022, operating expenses on a constant currency basis was \$32.7 million, representing a 41% decrease from the three months ended September 30, 2021. For the nine months ended September 30, 2022, operating expenses on a constant currency basis was \$108.7 million, representing a 71% decrease from the nine months ended September 30, 2021. On a constant currency basis, operating expenses decreased for both the three and nine months ended September 30, 2022 primarily due to lower advertising and marketing spend and lower payroll-related costs in the U.S. segment as a result of the Realignment, reduced costs associated with the timing of Ginkgo milestones and a cancellation of beauty-focused product development spending in the U.S. segment as well as an expected credit loss allowance revaluation recognized in the three- and nine-month comparative periods, partially offset by higher restructuring costs related to the Realignment, including the planned exit of the Stayner Facility.

### Net income (loss)

For the three months ended September 30, 2022, net loss on a constant currency basis was \$36.5 million, representing a 147% reduction in net income from the three months ended September 30, 2021. For the nine months ended September 30, 2022, net loss on a constant currency basis was \$89.9 million, representing a 66% improvement from the nine months ended September 30, 2021.

### Adjusted EBITDA

For the three months ended September 30, 2022, Adjusted EBITDA on a constant currency basis was \$(22.0) million, representing a 53% improvement from the three months ended September 30, 2021. For the nine months ended September 30, 2022, Adjusted EBITDA on a constant currency basis was \$(59.9) million, representing a 55% improvement from the nine months ended September 30, 2021. The improvement in Adjusted EBITDA for both the three and nine months ended September 30, 2022 on a constant currency basis was primarily driven by decreases in general and administrative expenses, sales and marketing expenses, and research and development expenses as a result of the Company's strategic Realignment and an improvement in gross profit.

### Cash and cash equivalents & short-term investments

Cash and cash equivalents and short-term investments on a constant currency basis decreased 7% to \$937.2 million as of September 30, 2022 from \$1.0 billion as of December 31, 2021. The decrease in cash and cash equivalents and short-term investments is primarily due to cash flows used in operating activities in 2022.

## Liquidity and Capital Resources

As of September 30, 2022, we had \$633.3 million in cash and cash equivalents and \$255.5 million in short-term investments, which comprise the majority of the Company's cash position. We believe that the existing cash and cash equivalents and the short-term investments will be sufficient to fund the business operations and capital expenditures over the next twelve months. The following table summarizes the cash flows from operating, investing and financing activities:

(In thousands of U.S. dollars)

	Nine months ended September 30,	
	2022	2021
Cash flows used in operating activities	\$ (64,576)	\$ (117,678)
Cash flows used in investing activities	(160,300)	(110,236)
Cash flows used in financing activities	(2,277)	(13,164)
Effect of foreign currency translation on cash and cash equivalents	(26,524)	5,622
Net change in cash	\$ (253,677)	\$ (235,456)

**Comparison of cash flows between the nine months ended September 30, 2022 and the nine months ended September 30, 2021****Operating activities**

During the nine months ended September 30, 2022, we used \$64.6 million of cash in operating activities as compared to cash used of \$117.7 million in the nine months ended September 30, 2021, representing a decrease in cash used of \$53.1 million. This change is primarily driven by a \$63.1 million increase in net income after adjusting for non-cash items during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

**Investing activities**

During the nine months ended September 30, 2022, we used \$160.3 million of cash in investing activities, compared to \$110.2 million of cash used in investing activities during the nine months ended September 30, 2021, representing an increase of \$50.1 million in cash used by investing activities. This change is primarily driven by higher levels of short-term investments, partially offset by the purchase of the PharmaCann option during the nine months ended September 30, 2021, lower purchases of property, plant and equipment and an increase in repayments and decrease in disbursements related to loans receivable with related parties.

**Financing activities**

During the nine months ended September 30, 2022, cash used in financing activities was \$2.3 million, compared to \$13.2 million of cash used in financing activities during the nine months ended September 30, 2021, representing a decrease of \$10.9 million in cash used in financing activities. This change is primarily driven by a decrease of \$11.0 million in withholding taxes paid on share-based awards during the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021.

**Cash Requirements**

The Company's cash requirements have not changed significantly since the filing of the Annual Report.

**Critical Accounting Policies and Estimates**

Our critical accounting policies and estimates are discussed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report. Our critical accounting policies and estimates have not changed significantly since the filing of the Annual Report.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

The Company is exposed to certain market risks, including changes from foreign currency exchange rates related to our international operations. Except as updated below, the Company's market risks have not changed significantly from that disclosed in Item 7A, "Quantitative and Qualitative Disclosures About Market Risk" in our Annual Report.

**Foreign currency risk**

The Company's condensed consolidated financial statements included in Part I, Item 1. "Financial Statements" of this Quarterly Report are expressed in U.S. dollars. The Company is exposed to foreign currency risk based on its net assets, liabilities, and revenues denominated in foreign currencies, including Canadian dollars and Israeli new shekels. As a result, we are exposed to foreign currency translation gains and losses. Revenue and expenses of all foreign operations are translated into U.S. dollars at the foreign currency exchange rates that approximate the rates in effect during the period when such items are recognized. Appreciating foreign currencies relative to the U.S. dollar will positively impact operating income and net earnings, while depreciating foreign currencies relative to the U.S. dollar will have an adverse impact.

A 10% change in the exchange rates for the Canadian dollar would have affected the carrying amount of the net assets by approximately \$79.9 million and \$87.8 million as of September 30, 2022 and December 31, 2021, respectively. The corresponding impact would be recorded in accumulated other comprehensive income. We have not historically engaged in hedging transactions and do not currently contemplate engaging in hedging transactions to mitigate foreign exchange risks. As we continue to recognize gains and losses in foreign currency transactions, depending upon changes in future currency rates, such gains and losses could have a significant, and potentially adverse, effect on the Company's results of operations.

During the three months ended September 30, 2022 and 2021, the Company had foreign currency loss on translation of \$60.6 million and \$22.8 million, respectively. During the nine months ended September 30, 2022 and 2021, the Company had foreign currency gain (loss) on translation of \$(68.8) million and \$6.9 million, respectively.

**Item 4. Controls and Procedures.***(a) Evaluation of Disclosure Controls and Procedures.*

The Company's management, with the participation of the Chief Executive Officer and the Chief Financial Officer, performed an evaluation of the disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the "Exchange Act"), as of September 30, 2022. Based on that evaluation, management has concluded that, as of September 30, 2022, due to the existence of material weaknesses in the Company's internal control over financial reporting described below, the disclosure controls and procedures were not effective to provide reasonable assurance that the information required to be disclosed by us in reports we file or submit under the Exchange Act were recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC, and to ensure that the information required to be disclosed by us in reports that we file or submit under the Exchange Act, is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

*Material Weakness in Internal Controls Over Financial Reporting*

A material weakness is a deficiency, or combination of deficiencies in internal controls over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. As previously disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the "Annual Report"), we have identified the following material weaknesses:

- **Control Environment:**

We did not maintain an effective control environment. Specifically, our control environment (i) did not ensure that senior personnel in our accounting function engaged consistently in appropriate professional conduct and conduct consistent with our Code of Business Conduct and Ethics; and (ii) lacked personnel in our accounting function with appropriate level of knowledge and experience in U.S. GAAP sufficient to properly assess evidence and interpret accounting rules.

None of the personnel in the accounting function that engaged in misconduct were current or former executive officers of the Company. The control environment material weakness contributed to the goodwill and indefinite-lived intangible asset material weakness described below.

- **Goodwill and Indefinite-lived Intangible Asset Impairment Testing:**

We identified the following material weakness with respect to goodwill and indefinite-lived intangible asset impairment testing. We did not design and maintain effective controls to assess goodwill and indefinite-lived intangible assets for potential impairment as changes in the performance of and prospects for our U.S. reporting unit occurred. Specifically, we did not design and maintain effective controls to sufficiently assess the overall financial performance of and expectations for our U.S. reporting unit and certain macroeconomic, industry and market conditions when evaluating goodwill associated with our U.S. reporting unit and our Lord Jones® brand indefinite-lived intangible asset for potential impairment.

The material weakness in the control environment contributed to material misstatements related to the impairment of goodwill and indefinite-lived intangible assets that led to the restatement of the Company's condensed consolidated interim financial statements for the three and six months ended June 30, 2021. The material weaknesses create a reasonable possibility that a material misstatement to the consolidated financial statements would not be prevented or detected on a timely basis. The lack of personnel in our accounting function with appropriate level of knowledge and experience in U.S. GAAP sufficient to properly assess evidence and interpret accounting principles described above resulted in immaterial misstatements related to the accounting for derivatives, share-based compensation, earnings per share, and long-lived asset impairment.

### Remediation Plan and Status

As of the filing date, the Company has implemented or is in the process of implementing various initiatives intended to address the identified material weaknesses and strengthen our overall control environment. In this regard, some of our key remedial initiatives include:

Material Weakness	Control, Control Enhancement or Mitigant	Implementation Status	Management Testing Status	Remediation Status
Control Environment	<ul style="list-style-type: none"> <li>The Company's Chief Executive Officer and Chief Financial Officer have reinforced and will continue to reinforce on an ongoing basis the importance of adherence to the Company's policies, procedures and standards of conduct, including identifying misconduct and raising and communicating concerns;</li> </ul>	Completed	In Progress	Not Remediated
	<ul style="list-style-type: none"> <li>All accounting personnel that engaged in unprofessional conduct have been terminated or resigned from the Company and are in the process of being replaced with qualified personnel;</li> </ul>	Completed	In Progress	Not Remediated
	<ul style="list-style-type: none"> <li>We have enhanced our existing sub-certification process to include additional certifications regarding certain complex accounting topics and to include additional employees to increase accountability amongst Company personnel;</li> </ul>	Completed	In Progress	Not Remediated
	<ul style="list-style-type: none"> <li>We have expanded our compensation claw back provisions to incorporate all personnel who are subject to our enhanced sub-certification process;</li> </ul>	Completed	In Progress	Not Remediated
	<ul style="list-style-type: none"> <li>We have identified and are in the process of implementing organizational enhancements including (i) evaluating the sufficiency, experience and training of personnel within our accounting function and (ii) hiring accounting personnel with appropriate knowledge and experience in U.S. GAAP;</li> </ul>	In Progress	In Progress	Not Remediated
	<ul style="list-style-type: none"> <li>We are in the process of developing and implementing a training program for accounting and finance personnel to enhance their knowledge of U.S. GAAP outlined in our accounting policies, which are used in the preparation of the Company's consolidated financial statements; and</li> </ul>	In Progress	In Progress	Not Remediated
Asset Impairment Testing	<ul style="list-style-type: none"> <li>We have evaluated and will continue to regularly evaluate our policies and procedures relating to certain complex accounting topics and have begun implementing improvements in those policies and procedures.</li> </ul>	Completed	In Progress	Not Remediated

The Company will continue to review, optimize, and enhance its financial reporting controls and procedures. As the Company continues to evaluate and work to improve its internal control over financial reporting, the Company may implement additional measures to address the material weaknesses or certain of the remediation measures described above may be enhanced or modified. The material weaknesses will not be considered remediated until the applicable remediated controls operate for a sufficient period of time and management has concluded, through further testing, that these controls are operating effectively.

#### (b) Changes in Internal Control over Financial Reporting

Other than those material weaknesses identified and measures described above to remediate the material weaknesses identified in the prior year, there were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), that occurred during the quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

## PART II OTHER INFORMATION

### Item 1: Legal Proceedings.

The information set forth under Note 11(b), Contingencies, to the Company's condensed consolidated interim financial statements included in Part I, Item 1. "Financial Statements" of this Quarterly Report is incorporated herein by reference.

### Item 1A: Risk Factors.

An investment in us involves a number of risks. A detailed discussion of our risk factors appears in Part I, Item 1A. Risk Factors of the Annual Report. Any of the matters highlighted in the risk factors described in the Annual Report and the risk factors below could adversely affect our business, results of operations and financial condition, causing an investor to lose all, or part of, its, his or her investment. The risks and uncertainties described in the Annual Report and below are those we currently believe to be material, but they are not the only ones we face. If any of the risks described in the Annual Report, the following risk factors, or any other risks and uncertainties that we have not yet identified or that we currently consider not to be material, actually occur or become material risks, our business, prospects, financial condition, results of operations and cash flows and consequently the price of our securities could be materially and adversely affected.

***We are subject to disabilities as a result of the SEC Order that may expose us to increased future litigation and adversely affect our ability to raise capital.***

As of the date of the SEC Order, October 24, 2022, and for a period of three years thereafter, we are unable to rely on the safe harbor provisions regarding forward-looking statements provided by the Securities Act and the Exchange Act. Our inability to rely on these safe harbor provisions may expose us to increased future litigation in connection with forward-looking statements in our public disclosures.

Further, as of the date of the SEC Order, we have lost our status as a "well-known seasoned issuer" for a period of three years, which places limitations on the manner in which we can market our securities to the public, and we are unable to rely on the private offering exemptions provided by Regulations A and D under the Securities Act for a period of five years, which could impair our ability to raise additional capital in the private market quickly in response to changing requirements and market conditions.

***Our business, financial condition, results of operations and cash flows could be adversely affected by disruptions in the global economy caused by the ongoing conflict between Russia and Ukraine.***

The global economy has been negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the U.S., Canada, United Kingdom, and European Union have each imposed export controls on certain products and financial and economic sanctions on certain industry sectors and parties in Russia. Although we do not have any customers or direct supplier relationships in Russia or Ukraine, businesses in the United States and globally have experienced shortages in materials and increased costs for transportation, energy, and raw material due in part to the negative impact of the Russia-Ukraine military conflict on the global economy. Further escalation of geopolitical tensions related to the military conflict, including increased trade barriers or restrictions on global trade, could result in, among other things, cyberattacks, supply disruptions, lower consumer demand, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business, financial condition, results of operations and cash flows.

We are continuing to monitor the situation in Ukraine and globally and assessing its potential impact on our business. Although our business has not been, to the date of this Quarterly Report, materially impacted by the ongoing military conflict in Ukraine, it is impossible to predict the extent to which our operations, or those of our suppliers and vendors, will be impacted in the short and long term, or the ways in which the conflict may impact our business. The extent and duration of the military action, sanctions and resulting market disruptions are impossible to predict, but may be substantial. In addition, the effects of the ongoing conflict could heighten any of our known risks described in our Annual Report.

***There can be no assurance of continued growth in Israel and our performance in Israel depends on, among other things, our ability to continue to import cannabis into Israel and our joint venture partners.***

While our revenue in Israel has experienced a recent period of significant growth, our prior performance is not indicative of any potential future results in Israel. There can be no assurance that our recent growth in the Israeli market can be sustained or will continue. Our ability to manage and sustain revenue growth in Israel will depend on a number of factors, many of which are beyond our control, including, but not limited to, our ability to continue to import cannabis into Israel, changes in laws and regulations respecting the cultivation, production and marketing of dried flower, pre-rolls and oils in Israel, increased competition, our ability to produce sufficient volumes of our products to meet customer demand and our ability to maintain or grow our market share in Israel. Any of these factors could materially and negatively impact our growth in Israel.

In connection with the Realignment, we have begun to further leverage our strategic joint venture with Cronos GrowCo. Our current efforts to wind-down and ultimately exit the Stayner Facility have increased the importance of Cronos GrowCo to our business and operations. Once the Stayner Facility is closed, Cronos GrowCo's production facilities will be our principal source of raw materials. Therefore, our performance in Israel is reliant on our ability to acquire such raw materials on a timely and cost-effective basis from Cronos GrowCo and to continue to import such raw materials and cannabis products to Israel from Cronos GrowCo. There is no guarantee that we will be able to successfully execute our strategy to expand production at Cronos GrowCo or that we will be able to obtain the regulatory approvals, licenses and permits required for both the export of cannabis from Canada and the import of cannabis into Israel. See *"We may not successfully execute our production capacity strategy"* included under Part I, Item 1A "Risk Factors" of the Annual Report.

Additionally, our performance in Israel depends on the results of Cronos Israel, which holds the certificates and corresponding permits required for the cultivation, production and marketing of cannabis in Israel and is responsible for distributing PEACE NATURALS® branded cannabis products to the Israeli medical cannabis market. Cronos Israel is a strategic joint venture operating in a foreign country and is therefore subject to all the risks normally associated with an investment in a joint venture and the conduct of business in a foreign country, any of which could materially and negatively impact the performance of Cronos Israel. See *"Our use of joint ventures may expose us to risks associated with jointly owned investments"* and *"Investments and joint ventures outside of Canada and the U.S. are subject to the risks normally associated with any conduct of business in foreign countries, including varying degrees of political, legal, regulatory and economic risk"* included under Part I, Item 1A "Risk Factors" of the Annual Report for a discussion of the risks relating to joint ventures and foreign investments.

## **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

## **Item 3. Defaults Upon Senior Securities.**

None.

## **Item 4. Mine Safety Disclosures.**

Not applicable.

## **Item 5. Other Information.**

### ***Griese Letter Agreement***

On November 7, 2022, the Company, Cronos USA Client Services LLC ("Cronos USA") and Hortican Inc. ("Hortican"), both wholly-owned subsidiaries of the Company, entered into a separation agreement with John Griese (the "Separation Agreement"), who previously ceased to serve as Senior Vice President, Head of Operations (North America) of the Company, effective as of the close of business on October 18, 2022. Jeff Jacobson, then Senior Vice President, Head of Growth (North America) for Cronos Group, assumed Mr. Griese's responsibility for overseeing Cronos Group's operations within North America.

Under the Separation Agreement, Mr. Griese will continue to be employed for purposes of transitioning his duties to Mr. Jacobson until January 18, 2023 (the "Resignation Date"). Following the Resignation Date, subject to Mr. Griese's entering into a release of claims in favor of the Company and its affiliates and related entities, Mr. Griese will be entitled to (1) a lump sum payment of \$139,615, which represents six months of Mr. Griese's annual base salary, (2) a lump sum payment of \$4,688, which is equal to six months of Cronos USA's portion of Mr. Griese's benefits premium, in lieu of the continuation of group insured benefits following Mr. Griese's resignation, and (3) continued vesting of any outstanding and unvested equity awards in accordance with the terms and conditions of the applicable award agreements, subject to Mr. Griese's compliance with his post-employment obligations. Mr. Griese is also eligible to receive an annual bonus for the Company's 2022 fiscal year, subject to the terms and conditions of the Company's short-term incentive compensation program and Mr. Griese entering into the aforementioned release of claims.

Pursuant to the Separation Agreement, Mr. Griese is subject to an ongoing non-disparagement provision, and the ongoing confidentiality and intellectual property provisions contained in the Executive Employment Agreement, effective January 10, 2022, by and among Mr. Griese, Cronos USA and the Company.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

**Jacobson Promotion**

On November 7, 2022, Jeffrey Jacobson was promoted from Senior Vice President, Head of Growth (North America) to Chief Growth Officer. In connection with his promotion, Mr. Jacobson's annual base salary increased to CAD \$420,000, his annual target bonus opportunity under the Company's short-term incentive compensation plan increased to 115% of his base salary; and his target annual long-term incentive compensation opportunity increased to 115% of his base salary. All other terms and conditions of Mr. Jacobson's employment remained the same.

**Item 6. Exhibits**

The exhibits listed in the Exhibit Index immediately below are filed as part of this Quarterly Report, which Exhibit Index is corporate by reference herein.

<b>Exhibit Number</b>	<b>Exhibit Index</b>
3.1	<a href="#">Certificate of Continuance, Notice of Articles and Articles of Cronos Group Inc. (incorporated by reference to Exhibit 3.1 to the Quarterly Report on Form 10-Q of Cronos Group Inc., filed August 6, 2020).</a>
31.1*	<a href="#">Certification of the Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
31.2*	<a href="#">Certification of the Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a>
32.1**	<a href="#">Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
32.2**	<a href="#">Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a>
10.01	<a href="#">Letter Agreement by and among Jeffrey Jacobson and Hortican Inc., dated November 7, 2022.</a>
10.02	<a href="#">Letter Agreement by and among John Griese, Cronos USA Client Services LLC, and Hortican Inc., dated November 7, 2022.</a>
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.

---

\* Filed herewith.

\*\* Furnished herewith and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CRONOS GROUP INC.

By: /s/ Robert Madore

Robert Madore  
Chief Financial Officer

November 7, 2022

By: /s/ Carlos Cortez

Carlos Cortez  
Vice President, Controller, and Principal Accounting Officer

November 7, 2022

November 7, 2022

Jeff Jacobson  
At the Address on file with the Company

Dear Jeff,

This letter agreement (this "Letter Agreement"), effective as of November 7, 2022 (the "Effective Date"), sets forth the terms and conditions of our agreement regarding your new position as Chief Growth Officer. Capitalized terms used in this Letter Agreement that are not defined herein have the meanings set forth in your employment agreement with Hortican Inc., a corporation organized under the federal laws of Canada (the "Company"), dated as of June 21, 2019 (the "Employment Agreement").

1. **Position and Reporting Relationship.**

As of the Effective Date, your employment with the Company will continue in the position of Chief Growth Officer of Cronos Group Inc. ("Cronos Group"). You will continue to be instructed by report to the Chief Executive Officer of Cronos Group.

2. **Compensation.**

As of the Effective Date: (a) the Base Salary will increase to CAD \$420,000, less applicable deductions and withholdings; (b) your annual target bonus opportunity will increase to 115% of Base Salary; and (c) your target annual long-term incentive opportunity over shares of Cronos Group will increase to 115% of Base Salary.

3. **General.**

Except as expressly modified by this Letter Agreement, all terms and conditions of your employment, as set out in the Employment Agreement, including, without limitation, Section 6 ("Termination of Employment") and Section 7 ("Restrictive Covenants"), remain unchanged and continue in full force and effect.

4. **Independent Legal Advice.**

You acknowledge that you have been encouraged to obtain independent legal advice regarding the execution of this Letter Agreement, and that you have either obtained such advice or voluntarily chosen not to do so, and hereby waive any objections or claims you may make resulting from any failure on your part to obtain such advice.

5. **Counterparts.**

This Letter Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Agreement by electronic transmission, including in portable document format (.pdf), shall be deemed as effective as delivery of an original executed counterpart of this Letter Agreement.

If you agree that this Letter Agreement correctly memorializes our understandings, please sign and return this Agreement, which shall become a binding agreement as the Effective Date.

Sincerely,

**HORTICAN INC.**

By: /s/ Michael Gorenstein  
Name: Michael Gorenstein  
Title: President and Chief Executive Officer

**CRONOS GROUP INC.**

By: /s/ Michael Gorenstein  
Name: Michael Gorenstein  
Title: President and Chief Executive Officer

Accepted and Agreed:

/s/ Jeff Jacobson  
**Jeff Jacobson**

Date: November 7, 2022

November 7, 2022

John Griese  
At the Address on file with the Company

Dear John,

This letter agreement (this "Letter Agreement"), effective as of the date hereof (the "Effective Date"), sets forth the terms and conditions of our agreement regarding the separation of your employment with Cronos USA Client Services LLC, a limited liability company incorporated in the State of Delaware ("CCS"), and Hortican Inc., a corporation organized under the federal laws of Canada ("Hortican"), wholly owned subsidiaries of Cronos Group Inc., a corporation organized under the laws of the Province of British Columbia ("Cronos Group"). Unless context otherwise requires, capitalized terms used in this Letter Agreement that are not defined herein have the meanings set forth in your Employment Agreement with the CCS, dated as of January 10, 2022 (the "Employment Agreement"). For the avoidance of doubt, this Letter Agreement supersedes our letter dated October 18, 2022 regarding your separation from the Company.

**1. Resignation.**

- (a) As of the January 18, 2023 (the "Separation Date"), you voluntarily and irrevocably resign from (i) your employment with CCS and Hortican (together, the "Company"), and (iii) all other positions you may hold as an officer or director (or similar or equivalent position) of CCS, Hortican, Cronos Group or any subsidiary thereof (collectively, the "Resignations"). CCS, Hortican and Cronos Group hereby accept, acknowledge and agree to the Resignations. If any other documentation is necessary to properly effectuate the Resignations, you agree to cooperate reasonably and promptly in executing and delivering such documentation at the request of the Company or Cronos Group.
- (b) From the Effective Date to the Separation Date: (i) you shall continue to be employed by CCS and Hortican but shall cease to serve as Senior Vice President, Head of Operations of Cronos Group, (ii) you shall not perform any work except responding to inquiries in a timely manner to facilitate the transition of your duties and responsibilities; (iii) the Company may in good faith reassign or reduce your duties and responsibilities and restrict your network access; and (iv) you shall continue to be paid the Base Salary, and shall direct the Company as to whether the Base Salary should be paid by CCS as set forth in the Employment Agreement or by Hortican as set forth your letter agreement with Hortican and CCS dated August 26, 2022.
- (c) The Company shall: (i) pay any accrued but unpaid vacation pay owing for the period up to the Separation Date; and (ii) reimburse your documented expenses properly incurred prior to the Effective Date in accordance with the Company's expense reimbursement policy. Except as set forth in Section 2(a)(ii) of this Letter Agreement, your participation in CCS's benefit plans shall end on the Separation Date.

**2. Separation Benefits.**

Contingent on your execution and non-revocation of the Release and Waiver of Claims attached hereto as Exhibit A (the "Release") on or following the Separation Date in accordance with the timing set forth therein, and subject to: (i) Section 3 of this Letter Agreement, (ii) your compliance with the terms and conditions of this Letter Agreement and the post-employment obligations set forth in Article 7 of the Employment Agreement, including without limitation, as relates to confidentiality, intellectual property, and return of property, in consideration of amounts in excess of the minimum requirements under applicable law:

- (a) CCS shall, in full satisfaction of the Company's obligations to you:
- i. pay you US \$139,615, which represents six (6) months of your annual base salary, payable by way of lump sum payment within sixty (60) days after the Separation Date;
  - ii. pay you US \$4,688.04, which is equal to six (6) months of the employer portion of your benefits premiums, in lieu of continuing your group insured benefits following the termination of your employment; and
  - iii. continue your eligibility to receive an annual cash award in respect of the 2022 fiscal year (the "Bonus") and determine the amount of the Bonus, if any, based on the criteria set forth in the Cronos Group Discretionary Short-Term Incentive Compensation Program (the "STIC Program"). The Bonus, if any, shall be: (A) paid on the same date on which awards under STIC Program are provided to other Cronos Group executive officers in respect of the 2022 fiscal year, and (B) determined as though you were actively employed during the entire 2022 fiscal year. For the avoidance of doubt, you shall not be eligible to receive an annual cash award under the STIC Program in respect of the 2023 fiscal year; and
- (b) Cronos Group shall, in full satisfaction of its obligations to you, continue the vesting of any outstanding and unvested equity awards held by you as of the Separation Date in accordance with the terms and conditions of the applicable award agreements as though you continued to provide services to the Company or Cronos Group until the original vesting dates. For the avoidance of doubt, except as set forth in this Section 2(b), your entitlements in respect of any equity-based awards shall be governed by the terms and conditions of the applicable equity award plan and the applicable award agreements.

You understand and agree that the entitlements under this Section 2 are provided in satisfaction of your entitlements to notice of termination, pay in lieu of notice, termination pay, and severance pay owing from the Company and their affiliates, whether under the Employment Agreement, any employee benefit plan sponsored by the Company or any of its affiliates, applicable law (including the common law), or otherwise. You shall not be entitled to any other payments or benefits except as specifically provided herein.

**3. Clawback Policy.**

You understand and agree that any cash, equity or equity-based compensation paid or provided pursuant to Section 2 of this Letter Agreement is subject to the terms and conditions of Cronos Group's Clawback Policy in effect from time to time, and may be subject to a requirement that such compensation be repaid to the Company after it has been distributed to you.

**4. Restrictive Covenants; Return of Materials.**

You hereby affirm that the restrictive covenants and other post-employment obligations contained in the Employment Agreement are and shall remain in effect and enforceable in accordance with the terms of the Employment Agreement, and you hereby reaffirm the existence and reasonableness of those obligations (including, without limitation, any non-disclosure and non-disparagement obligations). The Company and Cronos Group agree to direct their officers not to make any statement or announcement that disparages, defames, or slanders you.

**5. Cooperation with Litigation, Investigations and Regulatory Proceedings.**

You agree, upon the Company's request, to cooperate with the Company in any investigation, litigation, arbitration or regulatory proceeding regarding events that occurred during your tenure with the Company and/or its affiliates, including by making yourself reasonably available to consult with the Company's counsel. The Company shall reimburse you for reasonable out-of-pocket expenses that you incur in extending such cooperation, so long as you provide satisfactory documentation of the expenses.

Cronos Group hereby affirms that the Indemnity Agreement between you and Cronos Group shall remain in effect in accordance with its terms following the Separation Date.

6. **Deductions and Withholdings.**

You understand and agree that the Company shall make such deductions and withholdings from your remuneration and any other payments or benefits provided to you pursuant to this Letter Agreement as may be required by law.

7. **Amendments.**

This Letter Agreement may only be amended by written agreement executed by CCS, Hortican, Cronos Group and you.

8. **Independent Legal Advice.**

You acknowledge that you have been encouraged to obtain independent legal advice regarding the execution of this Letter Agreement, and that you have either obtained such advice or voluntarily chosen not to do so, and hereby waive any objections or claims you may make resulting from any failure on your part to obtain such advice.

9. **Expenses.**

All costs, fees and expenses incurred in connection with this Letter Agreement and the transactions contemplated by this Letter Agreement including all costs, fees and expenses of representatives of the parties hereto, shall be paid by the party incurring such cost, fee or expense.

10. **Counterparts.**

This Letter Agreement may be executed in one or more counterparts, each of which when executed shall be deemed to be an original but all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Letter Agreement by electronic transmission, including in portable document format (.pdf), shall be deemed as effective as delivery of an original executed counterpart of this Letter Agreement.

If you agree that this Letter Agreement correctly memorializes our understandings, please sign and return this Letter Agreement, which shall become a binding agreement as of the Effective Date.

Sincerely,

**CRONOS GROUP INC.**

By: /s/ Michael Gorenstein  
Name: Michael Gorenstein  
Title: Chief Executive Officer and President

**CRONOS USA CLIENT SERVICES LLC**

By: /s/ Michael Gorenstein  
Name: Michael Gorenstein  
Title: Chief Executive Officer and President

**HORTICAN INC.**

By: /s/ Michael Gorenstein  
Name: Michael Gorenstein  
Title: Chief Executive Officer and President

Accepted and Agreed:

/s/ John Griese  
**JOHN GRIESE**

Date: November 7, 2022

*[Signature Page to Letter Agreement]*

## Exhibit A

### RELEASE AND WAIVER OF CLAIMS

**GENERAL RELEASE AND WAIVER OF CLAIMS** (this “**Release**”), by the undersigned (hereinafter called the “**Releasor**”) in favor of Cronos Group Inc. (“**Cronos Group**”) and its subsidiaries, including Cronos USA Client Services LLC (“**Cronos USA**”) and Hortican Inc. (“**Hortican**”, together with Cronos Group and CCS, the “**Employer**”) and affiliates, stockholders, beneficial owners of its stock, its current or former officers, directors, employees, members, attorneys and agents, and their predecessors, successors and assigns, individually and in their official capacities (hereinafter called the “**Releasees**”).

**WHEREAS**, Releasor has been employed by Cronos USA and Hortican as Senior Vice President, Head of Operations of Cronos Group;

**WHEREAS**, Releasor resigned from his employment with Cronos USA and Hortican effective as of January 18, 2023; and

**WHEREAS**, Releasor is seeking certain payments under Section 6.3 of the Employment Agreement entered into by Cronos USA, the Releasor and, solely for the purposes specified therein, Cronos Group, dated January 10, 2022 (hereinafter called the “**Employment Agreement**”), as set forth in the Letter Agreement between Cronos USA, Hortican, Cronos Group and Releasor dated November 7, 2022 (hereinafter called the “**Letter Agreement**”), that are conditioned on the effectiveness of this Release.

**NOW, THEREFORE**, in consideration of such payments and benefits and the covenants and agreements set forth in the Letter Agreement, the parties agree as follows:

1. **GENERAL RELEASE.** Releasor knowingly and voluntarily waives, terminates, cancels, releases and discharges forever the Releasees from any and all suits, actions, causes of action, claims, allegations, rights, obligations, liabilities, demands, entitlements or charges (collectively, “**Claims**”) that Releasor (or Releasor’s heirs, executors, administrators, successors and assigns) has or may have, whether known, unknown or unforeseen, vested or contingent, by reason of any matter, cause or thing occurring at any time before and including the date of this Release, including all claims arising under or in connection with Releasor’s employment, or termination or resignation of employment with the Employer, including, without limitation: Claims under United States federal, state or local law and the national, provincial or local law of any foreign country (statutory or decisional), including without limitation Canada, for wrongful, abusive, constructive or unlawful discharge or dismissal, for breach of any contract, or for discrimination based upon race, color, ethnicity, sex, age, national origin, religion, disability, sexual orientation, or any other unlawful criterion or circumstance, including rights or Claims under the Age Discrimination in Employment Act of 1967 (“**ADEA**”), the Older Workers Benefit Protection Act of 1990 (“**OWBPA**”), violations of the Equal Pay Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans with Disabilities Act of 1991, the Employee Retirement Income Security Act of 1974 (“**ERISA**”), the Fair Labor Standards Act, the Worker Adjustment Retraining and Notification Act, the Family Medical Leave Act, the Ontario *Employment Standards Act, 2000*, the Ontario *Human Rights Code*, the Ontario *Pay Equity Act*, the Ontario *Occupational Health and Safety Act*, and the Ontario *Workplace Safety and Insurance Act, 1997*, including all amendments to any of the aforementioned acts; and violations of any other federal, state, provincial or municipal fair employment statutes or laws, including, without limitation, violations of any other law, rule, regulation, or ordinance pertaining to employment, wages, compensation, hours worked, or any other Claims for compensation or bonuses, whether or not paid under any compensation plan or arrangement; breach of contract; tort and other common law Claims (including, without limitation, any common law Claims to notice of termination, pay in lieu of notice of termination, termination pay or severance pay); defamation; libel; slander; impairment of economic opportunity; defamation; sexual harassment; retaliation; attorneys’ fees; emotional distress; intentional infliction of emotional distress; assault; battery, pain and suffering; and punitive or exemplary damages (the “**Released Matters**”). In addition, in consideration of the provisions of this Release, Releasor further agrees to waive any and all rights under the laws of any jurisdiction in the United States, Canada, or any other country, that limit a general release to those Claims that are known or suspected to exist in Releasor’s favor as of the Release

Effective Date (as defined below). Releasor further represents and acknowledges that the Releasees have complied with the *Human Rights Code* (Ontario) in respect of the Releasor's employment and the cessation of such employment.

Thus, notwithstanding the purpose of implementing a full and complete release and discharge of the claims released by this Release, Releasor expressly acknowledges that this Release is intended to include in its effect, without limitation, all claims which Releasor does not know or suspect to exist in his favor at the time of execution hereof arising out of or relating in any way to the subject matter of the actions referred to herein above and that this Release contemplates the extinguishment of any such claims.

2. **SURVIVING CLAIMS.** Notwithstanding anything herein to the contrary, this Release shall not:
  - (i) release any Claims for payment of amounts payable under the Letter Agreement (including, without limitation, under Section 2 thereof);
  - (ii) release any Claim for employee benefits under plans covered by ERISA to the extent any such Claim may not lawfully be waived or for any payments or benefits under any Employer plans that have vested (including any 401(k) plan) according to the terms of those plans;
  - (iii) release any Claim or right Releasor may have pursuant to indemnification, advancement, defense, or reimbursement pursuant to any applicable D&O policies, any similar insurance policies, applicable law or otherwise;
  - (iv) release any Claim that may not lawfully be waived in a private agreement between the parties; or
  - (v) limit Releasor's rights under applicable law to provide truthful information to any governmental entity or to file a charge with or participate in an investigation conducted by any governmental entity. Notwithstanding the foregoing, Releasor agrees to waive Releasor's right to recover monetary damages in connection with any charge, complaint or lawsuit filed by Releasor or anyone else on Releasor's behalf (whether involving a governmental entity or not); provided that Releasor is not agreeing to waive, and this Release shall not be read as requiring Releasor to waive, any right Releasor may have to receive an award for information provided to any governmental entity.

3. **ADDITIONAL REPRESENTATIONS.** Releasor further represents and warrants that Releasor has not filed any civil action, suit, arbitration, administrative charge, or legal proceeding against any Releasees nor, has Releasor assigned, pledged, or hypothecated as of the Release Effective Date any Claim to any person and no other person has an interest in the Claims that he is releasing.

4. **ACKNOWLEDGMENT BY RELEASOR.** Releasor acknowledges and agrees that Releasor has read this Release in its entirety and that this Release is a general release of all known and unknown Claims. Releasor further acknowledges and agrees that:
  - (i) this Release does not release, waive or discharge any rights or Claims that may arise for actions or omissions after the Release Effective Date and Releasor acknowledges that he is not releasing, waiving or discharging any ADEA Claims that may arise after the Release Effective Date;
  - (ii) Releasor is entering into this Release and releasing, waiving and discharging rights or Claims only in exchange for consideration which he is not already entitled to receive;

- (iii) Releasor has been advised, and is being advised by the Release, to consult with an attorney before executing this Release; and
- (iv) Releasor has been advised, and is being advised by this Release, that he has been given at least twenty-one (21) days within which to consider the Release, but Releasor can execute this Release at any time prior to the expiration of such review period; and
- (v) Releasor is aware that this Release shall become null and void if he revokes his or her agreement to this Release within seven (7) days following the date of execution of this Release. Releasor may revoke this Release at any time during such seven-day period by delivering (or causing to be delivered) to the Employer written notice of his or her revocation of this Release no later than 5:00 p.m. Eastern time on the seventh (7<sup>th</sup>) full day following the date of execution of this Release (the “**Release Effective Date**”). Releasor agrees and acknowledges that a letter of revocation that is not received by such date and time shall be invalid and shall not revoke this Release.

5. **COOPERATION WITH INVESTIGATIONS AND LITIGATION.** Releasor agrees, upon the Employer’s reasonable request and consistent with Releasor’s reasonable business and personal obligations, to reasonably cooperate with the Employer in any investigation, litigation, arbitration or regulatory proceeding regarding events that occurred during Releasor’s tenure with the Employer or its affiliate, including making himself or herself reasonably available to consult with Employer’s counsel, to provide information and to give testimony. Employer shall reimburse Releasor for reasonable out-of-pocket expenses Releasor incurs in extending such cooperation, so long as Releasor provides satisfactory documentation of the expenses. Nothing in this Section is intended to, and shall not, restrict or limit Releasor from exercising his or her protected rights described in Sections 2, 4, 5 or 6 hereof or restrict or limit Releasor from providing truthful information in response to a subpoena, other legal process or valid governmental inquiry.

6. **RESTRICTIVE COVENANTS.** Releasor hereby affirms the restrictive covenants set forth in Article 7 of the Employment Agreement shall continue to apply following the Release Effective Date in accordance with their terms

7. **GOVERNING LAW.** To the extent not subject to federal law, this Release shall be governed by and construed in accordance with the law of the State of California applicable to contracts made and to be performed entirely within that state.

8. **SEVERABILITY.** If any provision of this Release should be declared to be unenforceable by any administrative agency or court of law, then the remainder of the Release shall remain in full force and effect.

9. **CAPTIONS; SECTION HEADINGS.** Captions and section headings used herein are for convenience only and are not a part of this Release and shall not be used in construing it.

10. **COUNTERPARTS; FACSIMILE SIGNATURES.** This Release may be executed in any number of counterparts, each of which when so executed and delivered shall be deemed an original instrument without the production of any other counterpart. Any signature on this Release, delivered by either party by photographic, facsimile or PDF shall be deemed to be an original signature thereto.

IN WITNESS WHEREOF I have hereunder set my hand this \_\_\_\_ day of \_\_\_\_\_, 2022.

**SIGNED AND DELIVERED**  
in the presence of:

Witness Signature

Print Name of Witness

Address of Witness

**JOHN GRIESE**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER  
PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Michael Gorenstein, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cronos Group Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Michael Gorenstein

Michael Gorenstein  
President and Chief Executive Officer  
(Principal Executive Officer)

Date: November 7, 2022

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO SECTION 302 OF  
THE SARBANES-OXLEY ACT OF 2002**

I, Robert Madore, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Cronos Group Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Robert Madore

---

Robert Madore  
Chief Financial Officer  
(Principal Financial Officer)

Date: November 7, 2022

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906  
OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2022 of Cronos Group Inc. (the "Company") as filed with the U.S. Securities and Exchange Commission (the "SEC") on the date hereof (the "Report"), I, Michael Gorenstein, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Michael Gorenstein

\_\_\_\_\_  
Michael Gorenstein

President and Chief Executive Officer

*(Principal Executive Officer)*

Date: November 7, 2022

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO 18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO SECTION 906  
OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q for the period ended September 30, 2022 of Cronos Group Inc. (the "Company") as filed with the U.S. Securities and Exchange Commission (the "SEC") on the date hereof (the "Report"), I, Robert Madore, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

1. The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Robert Madore

\_\_\_\_\_  
Robert Madore

Chief Financial Officer

*(Principal Financial Officer)*

Date: November 7, 2022

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the SEC or its staff upon request.

This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.